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1. Introduction
Neuropathic pain is a common form of chronic illness
resulting from nerve damage caused by trauma, surgery, infection 
or disease.
1 
It is estimated that at least 3% of the world’s 
population is affected by this condition, with up to 50% of 
postoperative patients being impacted. Neuronal voltage gated 
calcium channels (VGCC) mediate the transmembrane flow of 
calcium (Ca
2+
) in response to membrane depolarisation and are 
known to be integral to the transmission of pain. The CaV2.2 (N-
type) channel is a well-validated pain target and this has inspired 
many groups, including ourselves, to purse inhibitors of the 
CaV2.2 channel as potential analgesics.
2-17
 Despite the academic
and commercial efforts to develop inhibitors of the CaV2.2 
channel, only Prialt (Ziconitide), a synthetic version of peptide ω-
conotoxin MVIIA, has reached the clinic. However, its use is 
limited by its intrathecal mode of delivery and narrow therapeutic 
window. Of the most advanced small molecule candidates, Z160 
(1, Figure 1) failed to meet the primary endpoint in phase 2 
clinical trials, and the phase 2 clinical trial results of CNV-
2197944 (structure not disclosed) were disappointing. Alternate 
dosing regimens and other therapeutic uses for this compound are 
being explored.
18
 More recently, the CaV3.2 (T-type) channel has
also been recognised as a target for the development of 
analgesics,
19, 20
 and the combined inhibition of CaV2.2 and CaV3.2 
channels has an analgesic effect in rodent models.
20
 In recent 
years several inhibitors of the CaV3.2 channel have been 
reported.
21-32
 The positive results obtained in Phase Ib clinical 
trials with compound Z944 (2, Figure 1) were encouraging but 
further studies with this analogue have apparently not been 
pursued. NNC 55-0396 (3, Figure 1), a stable analogue of 
Mibefradil, has high selectivity for CaV3 channels over high-
voltage activated channels, although it was deemed unsuitable for 
further development.
33
 Despite the number of novel small-
molecule chemical entities being developed for these targets, not 
one has reached the market. A review by Beswick describes the 
ART ICLE  INFO ABST RACT  
Article history: 
Received 
Received in revised form 
Accepted 
Available online 
Both N- and T-type calcium ion channels have been implicated in pain transmission and the N-
type channel is a well validated target for the treatment of neuropathic pain. An SAR 
investigation of a series of substituted aminobenzothiazoles identified a subset of five 
compounds with comparable activity to the positive control Z160 in a FLIPR-based intracellular 
calcium response assay measuring potency at both CaV2.2 and CaV3.2 channels. These 
compounds may form the basis for the development of drug leads and tool compounds for 
assessing in vivo effects of variable modulation of CaV2.2 and CaV3.2 channels. 
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Figure 1. Chemical structures of Z160 1, Z944 2 and NNC 55-0396 3.  
development of small-molecule inhibitors of CaV2.2 and CaV3 
channels in recent years and pointedly notes that recent clinical 
studies outcomes have been disappointing.
2
 Since chronic 
neuropathic pain is a widespread and debilitating condition, and 
there is increasing concern about opioid dependence amongst 
chronic pain sufferers, there is a pressing need to pursue new 
structural classes of neuronal calcium ion channel blockers. 
For a number of years we have conducted an academic 
research program aimed at developing small-molecule inhibitors 
of the CaV2.2 channel, initially concentrating on type-III 
peptidomimetics of ω-conotoxin GVIA,
34
 a 27-residue peptide 
that binds selectively and essentially irreversibly to CaV2.2 
channels.
13-17
 The structure of two of these peptidomimetics (4 
and 5), that contain a benzothiazole scaffold core, are shown in 
Figure 2.
16
 Their affinity for rat brain CaV2.2 channels, as 
measured by a radioligand displacement assay with 
125
I-GVIA, 
was encouraging. In an effort to shorten the synthetic route to this 
class of CaV2.2 inhibitor, as well as reduce the molecular weight 
of the peptidomimetics, ‘truncated’ analogues (6a and 7a) were 
synthesized.
17
 The guanidinium analogue 7a retained similar 
activity to compound 5. It should be noted that the radioligand 
displacement assay can over-estimate the functional activity of a 
small molecule CaV2.2 inhibitor by up to an order of 
magnitude,
14
 and consequently, the inhibition of intracellular 
calcium responses in living SH-SY5Y neuroblastoma cells, as 
measured on a FLIPR (Fluorescence Imaging Plate Reader) has 
become our primary method of screening CaV2.2 blockers. 
Similarly, the inhibition of intracellular calcium responses in 
HEK 293T expressing recombinant hCaV3.2 has become a useful 
screen for CaV3 activity. 
 
Figure 2. Non-peptide mimics of -conotoxin GVIA (4, 5), ‘the truncated’ 




In an endeavour to obtain greater potency for the CaV2.2 
channel and to also investigate the potential of these analogues to 
block the CaV3.2 channel, we embarked on a proof of principle, 
systematic investigation of the structure-activity relationship 
(SAR) for analogues of the ‘truncated’ series (6a and 7a). With 
an overarching aim of improving the physicochemical properties 
of this class of compound, as well as CaV2.2 and CaV3 potency, 
three regions of the benzothiazole-derived compounds were 
investigated; the electronegativity of the para-aromatic ring 
substituent (R
1
); N-methylation of the aminobenzothiazole 
nitrogen (R
2
), removing the H-donor at this site; and dimethyl 
analogues (R
3
), which are much more likely to be appropriate for 
CNS-active drugs (Figure 3). To enable accurate comparisons 
with the previous assay data, the ‘truncated’ analogues (6a and 
7a) were included as control compounds in the functional FLIPR 
assay, and Z160 1, and NNC 55-0396 3 were used as positive 
controls for the CaV2.2 and CaV3.2 channels respectively. The in 
vitro stability in rat plasma for representative classes of 
compounds is also disclosed.  
 
Figure 3. Schematic depiction of the SAR studies conducted of the low 
molecular weight, ‘truncated’ analogues, 6a and 7a. 
2. Chemistry 
The synthesis of benzothiazoles (10a-f), outlined in Scheme 1, 
was achieved by treatment of the aminobenzothiazole (8a-f) with 
the aldehyde 9
17





Scheme 1. Reagents and conditions: (a) (i) 9
17
, toluene, cat. p-TSA, reflux, 2 
days; (ii) EtOH, NaBH4, reflux, 5 h.  
 
The synthesis of the amino analogues (6a-f), the amino N-methyl 
analogues (12a-f) and their corresponding monoguanidino 
analogues (7a-f and 13a-f respectively) is described in Scheme 2. 
With the desired aminobenzothiazoles (10a-f) in hand, removal 
of the Boc protecting group under acidic conditions gave the 
corresponding amino analogues (6a, c-f), with the exception of 
the 4-OBn analogue (6b) in which deprotection was achieved 
utilizing TFA and thioanisole. Formation of the monoguanidino 
analogues (7a-f) was accomplished either in one step by 
treatment of the amine (6b,c and f) with 1H-pyrazole-
carboxamidine, or initial reaction of the amine (6a, d, and e) with 
N,N′-di-Boc-1H-pyrazole-1-carboxamidine followed by removal 
of the Boc groups under acidic conditions. In order to obtain the 
N-methylated analogues, the aminobenzothiazoles (10a-f) were 
reacted with NaH followed by the addition of 1.2 eq. of MeI. 
With the advanced intermediates (11a-f) in hand, the 
corresponding amino derivatives (12a-f) and corresponding 
guanidino analogues (13a-f) were obtained using similar 
transformations to those described above.  
Conversion of the benzothiazole-derived amines 6c and 6e to 
the N,N-dimethyl analogues, 14c and 14e respectively, was 
achieved by a reductive amination reaction; addition of 





 The use of similar conditions with the 
4-CF3 and 4-CN benzothiazole-derived amines (6d and 6e) 
proceeded to give an inseparable mixture of the mono-, bis- and 
tris- N-methylated compounds. Therefore, modification of the 
reaction conditions, specifically increasing the number of 
equivalents of paraformaldehyde and NaBH4, allowed the tris-N-
methylated benzothiazole-derived compounds 15d and 15f to be 
obtained. The benzothiazole-derived N,N-dimethyl amine 14f 
was obtained via a two-step procedure, as shown in Scheme 4.  
All final compounds were purified by preparative HPLC prior 
to being tested in the FLIPR assays.
  
 
Scheme 2. Reagents and conditions: (a) sat. HCl in dioxane or MeOH, DCM, RT, 1 h, purified by HPLC; OR TFA, thioanisole, RT, 1h, purified by HPLC (b) 
1H-pyrazole-1-carboxamidine, DIPEA, DMF, RT, 24 h, purified by HPLC; OR (i) N,N′-di-Boc-1H-pyrazole-1-carboxamidine, Et3N, DMF, RT, 12 h; (ii) AcCl, 
EtOH, RT, 6 h, purified by HPLC; (c) (i) NaH, THF, 0 °C, 30 min; (ii) 1.2 eq. MeI, RT, 4 h. 
 
Scheme 3. Reagents and conditions: (a) paraformaldehyde, NaBH4, cat. TFA, 
MeOH, RT, 24 h. 
 
 
Scheme 4. Reagents and conditions: (a) (i) 4-hydroxybenzaldehyde, toluene, 
cat. p-TSA, reflux, 7 days; (ii) EtOH, NaBH4, reflux, 5 h; (b) 3-chloro-N,N-
dimethylpropan-1-amine, K2CO3, THF, RT, 3 days. 
3. Biology 
Evaluation of the amino and monoguanidino analogues for 
inhibition of the CaV2.2 and CaV3.2 channels was evaluated 
utilizing a FLIPR calcium imaging assay. Experiments for 
CaV2.2 inhibition were performed with neuroblastoma SH-SY5Y 
cell line in the presence of the L-type calcium channel blocker 
Nifedipine. Experiments for CaV3.2 inhibition were performed 
with HEK 293T cells expressing recombinant human CaV3.2 α1 
subunit. These assays were performed at the natural resting 
membrane potential of the immortalised cell lines used, which 
are more depolarised than nerve cell in vivo. 
Assessment of the ‘truncated’ analogues 6a and 7a, utilizing 
the functional FLIPR-based assay for CaV2.2 activity, revealed 
them to be up to 5.6 times less potent than the positive control 
Z160 (Table 1 and Table 2). However, it was found that a 
number of substitutions on the parent structure 6a led to 
compounds with comparable activity to Z160. The data obtained 
with the amines 6a-f appear to show a strong correlation with the 
electron density in the phenoxy ring; electron withdrawing 
groups, especially at the para position, improve inhibition, with 
the cyano-amine 6f having equivalent activity to Z160. A similar 
trend is not obvious in the guanadinium series 7a-f, and the most 
potent compound of this series was the parent analogue 7a. The 
motivation to methylate at the aminobenzothiazole nitrogen came 
from a desire to remove the H-donor at this site and so it is 
interesting to note that a number of compounds in the amine 
series 12a-f showed promising activity (Table 3). Again, the 
results obtained with the guanidinium compounds 13a-f were less 
encouraging. Since tertiary amines are a common structural motif 
in marketed CNS-active drugs whereas primary amines are rare,
36
 
a selection of compounds were chosen for elaboration to the N,N-
dimethylamines (14c, 14e, 14f, 15d and 15f). It was extremely 
encouraging to find that four of these compounds (14c, 14e, 15d 
and 15f) gave comparable potencies to the positive control Z160 
(Table 4 and Figure 4).  
Table 1. Functional inhibition of calcium channels (h CaV2.2 and h CaV3.2) 
by the CaV2.2 blocker Z160 1 and the CaV3.2
 
blocker NNC 55-0396 3. 
CaV2.2    CaV3.2   








1 2 39 31-40 3 45 32-60 
3 2 7 2-15 0.3 2 0.8–6.3 
Turning to the inhibition data obtained against the CaV3.2 
channel, it is interesting to note that in these FLIPR-based 
intracellular calcium response assays, Z160 (1), a compound 
developed to target N-type calcium channels, shows similar 
potency towards both CaV2.2 and CaV3.2 channels. This is also 




Table 2. Functional inhibition of calcium channels (hCaV2.2 and hCaV3.2) by the amino and guanidino compounds 6a-f and 7a-f. 
 CaV2.2 CaV3.2  CaV2.2 CaV3.2 


















 10 218 173 - 274 ND >1000 ND 7a
b
 5 103 79 - 135 15 166 104 - 265 
6b 15 205 143 - 293 48 300 132 - 683 7b 9 253 212 - 300 34 319 259 - 803 
6c 3 106 90 - 124 78 688 393 - 1208 7c 7 244 211 - 282 8 288 248 - 335 
6d 2 59 48 - 72 18 112 48 - 229 7d 9 167 129 - 216 10 195 152 - 251 
6e 9 144 103 - 201 21 171 93 - 315 7e 4 130 111 - 151 16 270 196 - 372 
6f 2 41 31 - 56 6 109 86 - 140 7f 88 368 100 - 1354 4 326 305 - 345 
ND – Not determined 
 
 
Table 3. Functional inhibition of calcium channels (hCaV2.2 and hCaV3.2) by the N-methylaminobenzothiazoles 12a-f and 13a-f. 
 CaV2.2 CaV3.2  CaV2.2 CaV3.2 
















12a 7 49 33 - 78 16 95  39 - 234 13a 4 113 92 - 137 18 498 312 - 602 
12b 9 117 80 - 172 23 165 82 - 334 13b 42 432 267 - 698 24 332 246 - 597 
12c 7 98 66 - 144 114 492 154 - 1564 13c 8 100 66 - 152 21 521 425 - 639 
12d 11 283 231 - 346 14 248 151 - 383 13d 8 185 150 - 228 10 212 165 - 273 
12e 2 77 67 - 88 22 239 137 - 314 13e 13 202 145 - 281 42 771 581-1024 
12f 5 65 42 - 102 9 328 286 - 381 13f 7 143 112 - 184 6 153 125 - 186 
Table 4. Functional inhibition of calcium channels (hCaV2.2 and hCaV3.2) by 
the N, N-dimethyl amino compounds 14c, 14e and 14f, and the tris-N-
methylated benzothiazole-derived compounds 15d and 15f. 
CaV2.2    CaV3.2   








14c 2 40 31-50  ND >1000 ND 
14e 3 51 39-67 19 110 30-285 
14f 51 105 24-302 13 41 29-94 
15d 2 46 15-97 7 54 22-122 
15f 30 69 27-229 26 64 30-224 
ND – Not determined 
 
selectivity for CaV3 channels.
33
 Its activity is in the single digit 
micromolar range for both channels (Table 1). For the 
aminobenzothiazoles, it can be seen that none of the primary 
amines or guanidinium compounds showed any significant effect, 
except possibly 12a, but at an IC50=95 M, even its activity is 
marginal (Tables 2 and 3). This data is consistent with the 
original design of these compounds, which was based around 
selective N-type channel blockers.
37
 Amongst the N,N-
dimethylamines, however, three compounds (14f, 15d and 15f) 
showed promising activity against the CaV3.2 channel (Table 4 
and Figure 4). Further experiments using electrophysiological 
approaches to evaluate state-dependent inhibition will be 
performed in due course.  
Representative compounds from each structural class (6c, 7d, 
12e and 13e) were tested for their in vitro stability in rat plasma. 
All compounds showed good stability in rat plasma; after 24 h 
75% of the amino 6c remained, 91% of the monoguanidino 7d, 
100% of the N-methyl amino 12e and 95% of the N-methyl 
guanidine 13e; (n=3).  
The central nervous system multiparameter optimization 
(CNS MPO) desirability tool, developed by researchers at Pfizer 
Pharma Therapeutics, utilizes six important physicochemical 
properties to identify lead compounds with an increased chance 
of penetrating  
 
Figure 4. Activity of the N, N-dimethyl amino and tris-N-methylated 
benzothiazole-derived compounds over N-type and T-type calcium channels 
determined by fluorescent assays. Concentration-response curves for 
inhibition of CaV2.2. (A) and CaV3.2 (B) under application of various 
concentrations of the N, N-dimethyl amino compounds 14c, 14e and 14f, the 
tris-N-methylated benzothiazole-derived compounds 15d and 15f, and the 
controls Z160 (compound 1) and NNC 55-0396 (compound 3). IC50 values 
calculated are described in Tables 1 and 4. Data are presented as mean ± 
SEM, n = 3 - 4 independent experiments. 
the CNS; lipophilicity (ClogP); distribution coefficient at pH 7.4 
(ClogD); molecular weight; topological polar surface area 
  
(TPSA); number of hydrogen-bond donors (HBDs); and the most 
basic center (pKa).
38, 39
 A MPO desirability score of ≥ 4, on a 
scale of 0–6, indicates that the compound has a strong likelihood 
of being CNS-penetrating. The MPO score for Z160 was 
calculated to be 2.3, whereas the dimethylamine 14c, the most 
potent aminobenzothiazole against the CaV2.2 channel, has a 
value of 2.6. The failure of Z160 to progress beyond phase 2 
clinical trials may reflect its less than ideal physicochemical 
properties for a CNS-active drug, and so it is heartening that 
aminobenzothiazole analogues have been identified that have 
similar CaV2.2 and CaV3.2 potency as Z160 and slightly 
improved MPO scores. While there is clearly room for further 
improvement with respect to physicochemical properties, the 
compounds listed in Table 4 provide a guide for future 
endeavours, including their application as tool compounds in 
probing the in vivo effects of variable modulation of CaV2.2 and 
CaV3.2 channels in pain models. In addition, if the 
aminobenzothiazole-derived compounds do not enter the CNS, 
peripheral CaV2.2 and/or CaV3.2 blockers are still of interest as 
the analgesic potential associated with peripheral block is 
underexplored.  
4. Conclusions 
In summary, an SAR investigation of the previously published 
‘truncated’ analogues 6a and 7a has identified a subset of 
compounds with comparable potency to Z160 1 at the CaV2.2 
channel. Key improvements came from the incorporation of 
electron withdrawing groups on the phenoxy substituent and N-
methylation at both the aminobenzothiazole nitrogen and the 
pendant amine. Results from tests with representative examples 
revealed this class of compound to also have a prolonged in vitro 
half-life in rat plasma (>24 h). 
The recent surge in interest in the relevance of CaV3 channels 
in pain transmission prompted an investigation of the activity of 
the aminobenzothiazoles at the CaV3.2 channel. It was pleasing to 
note that a small number of compounds (14f, 15d and 15f) 
possess promising activity at this target. The analogues listed in 
Table 4 may also serve as useful tool compounds to investigate 
the in vivo effects of variable modulation of CaV2.2 and CaV3.2 
channels in pain models. For example, 14c appears to be highly 
selective for the N-type channel (as opposed to the two positive 
controls 1 and 3, which appear to be non-selective) while 14f 
shows some preference for the T-type channel, and 15d and 15f 
are equipotent at these channels. 
We are continuing to investigate the aminobenzothiazole 
scaffold, along with other scaffolds, for the future development 
of drug leads for the treatment of neuropathic pain. Testing of 
this class of molecule across a broad range off-targets, as well as 




5 .1 .1 .  General  Exper imental  
All starting materials and reagents were obtained from 
commercial suppliers and used without further purification. The 
synthesis of compounds 8c, 8d, 8e and 8f is reported in 
supplemental material. The aldehyde 9, and the 
aminobenzothiazoles 10a and 10b were synthesized according to 
references 16 or 17. Z160 1 was synthesized according to 
reference 4; N-(3-dimethylaminopropyl)-N’-ethylcarbodiimide-
assisted acylation of N-benzhydryl piperazine with 3,3-
diphenylpropanoic acid. NNC 55-0396 dihydrochloride 3 was 
provided by Alomone Labs (Jerusalem, Israel). Air- and 
moisture-sensitive reactions were performed under an argon/UHP 
nitrogen atmosphere. Column chromatography was performed 
using silica gel (100−200 mesh size) with indicated solvents. 
Thin-layer chromatography (TLC) was conducted with silica gel 
60 F254 precoated plates (0.25 mm) and visualized with UV, 
potassium permanganate, ceric ammonium molybdate as 
appropriate. All 
1
H NMR spectra were recorded on Bruker 400, 
500, 600 MHz spectrometers and have been reported in ppm 
using solvents as internal standards (CDCl3 at 7.26 ppm, DMSO-
d6 at 2.50 ppm and methanol-d4 at 3.31 ppm). Multiplicities are 
denoted as singlet (s), doublet (d), triplet (t), quartet (q),quintet 
(quin), multiplet (m) or prefixed broad (br), or a combination 
where necessary. All proton-decoupled 
13
C NMR spectra and J-
Modulated Spin Echo (JMOD) have been reported in ppm using 
solvents as internal standards (CDCl3 at 77.2 ppm, DMSO-d6 at 
39.5 ppm and Methanol-d4 at 49.2). 
19
F NMR spectra were 
recorded at 376 or 470 MHz operating frequencies. Compounds 
were analyzed for HRMS on a Bruker mass spectrometer using 
electrospray ionization or APCI in the positive ion mode. IR 
spectra were recorded on a Bruker-Tensor FT-IR spectrometer 
and have been reported in wavenumber (cm
−1
). Melting points 
were measured on a Bruker micromelting point apparatus. 
Preparative HPLC was performed on an Agilent 1260 Infinity 
Prep LC controller with an Agilent 1260 Infinity Absorbance 
detector using a Phenomenex Luna C8 column (21.2 x 150 mm, 
5 micron) with a 10 mL per minute flow rate. The elution method 
used for HPLC purification was gradient from 90% buffer 
A/10% buffer B to 10% buffer A/90% buffer B over 30 min, and 
then held at to 10% buffer A/90% buffer B for 10 min (buffer A 
= 0.1% TFA in MilliQ water, buffer B = 0.1% TFA in 80% 
MeCN/20% MilliQ water). 
5.1.2.  General  procedure  for  reductive  amination  
(Procedure  A) 
A mixture of the aldehyde 9
17
 (1.1 eq., 5.53 mmol) and the 
thiazolyl amine (1 eq., 4.61 mmol) were dissolved in dry toluene 
(150 mL). To this a catalytic amount of pTSA (0.05 eq., 0.23 
mmol) was added and the reaction mixture was refluxed using 
Dean-Stark apparatus for 2.5 days. The reaction mixture was 
cooled to ~70 °C. This solution containing the intermediate imine 
was added to a solution of NaBH4 (2 eq., 11.53 mmol) in dry 
EtOH (100 mL). After the reaction mixture was refluxed for 5 h, 
solvent was removed in vacuo and water was added. After 
extraction with DCM the combined organic layers were 
sequentially washed with water and brine, dried (Na2SO4) and the 
volatiles removed in vacuo. The crude product was purified by 
column chromatography.  
5.1.3.  General  procedure  for  methylat ion  
(Procedure  B) 
Under nitrogen atmosphere, the oil residue from sodium 
hydride (2.2 eq., 0.693 mmol) as removed by washing with dry 
petroleum ether. To this was added dry THF (6 mL) and the 
suspension cooled to 0 °C. After the dropwise addition of the 
compound to be methylated (1 eq., 0.287 mmol) in dry THF (6 
mL), the reaction was stirred at ambient temperature for 30 min. 
After recooling the solution to 0 
°
C, methyl iodide (1.2 eq., 0.315 
mmol) that had been passed through neutral alumina was added 
dropwise. After the reaction mixture was stirred at ambient 
temperature for 4 h the reaction was quenched with ice and 
extracted with DCM. The combined organic layers were washed 
with water and concentrated. The crude product was purified 
using column chromatography. 
5.1.4.  General  procedure  for  the  synthes is  of  amine 
target  compounds  (Procedure  C) 
  
To the Boc-protected compound (0.250 mmol, 1 eq.) in dry 
DCM was added a saturated solution of HCl in dioxane or MeOH 
(1 mL). After the reaction mixture was stirred at ambient 
temperature under an inert atmosphere for 2 h, volatiles were 
removed in vacuo and the crude product was purified by 
preparative HPLC. 
5.1.5.  General  procedure  for  the  synthes is  of  
guanidinium target  compounds  (Procedure  D) 
The free amine precursor (1 eq., 0.2 mmol) was dissolved in 
dry DMF (2 mL), N,N′-di-Boc-1H-pyrazole-1-carboxamidine (1 
eq., 0.2 mmol) and Et3N (1 eq., 0.2 mmol) were added and the 
reaction mixture stirred at ambient temperature under an inert 
atmosphere for 12 h. Ice and DCM (15 mL) were added to the 
reaction mixture, the organic layer was separated and the aqueous 
layer extracted with DCM (2 x 15 mL). The combined organic 
layers were successively washed with water and brine, dried over 
Na2SO4 and concentrated in vacuo. The crude product and 
purified by column chromatography.  
To the intermediate product (1 eq., 0.15 mmol), dissolved in 
dry EtOH (2 mL) at 0 °C, was added freshly distilled acetyl 
chloride (1.5 mL). After the reaction mixture was stirred at 
ambient temperature for 6 h, volatiles were removed in vacuo 
followed by the subsequent addition and removal of EtOH to 
remove excess HCl. The crude product was purified by 
preparative HPLC. 
5.1.6.  General  procedure  for  the  synthes is  of  
guanidinium target  compounds  (Procedure  E)  
To the amine precursor (1 eq., 0.115 mmol), dissolved in dry 
DMF (1 mL) and under an inert atmosphere, was added 1H-
pyrazole-1-carboxamidine (1.5 eq., 0.173 mmol) and DIPEA, 
TEA or K2CO3 (2 eq., 0.3 mmol). After the reaction mixture was 
stirred at ambient temperature for 24 h the volatiles were 
removed in vacuo and the crude product was purified by 
preparative HPLC.  
5.1.7.  Synthes is  of  ter t iary  amines  (Procedure  F)  
Following the procedure of Gribble,
35
 to the precursor (30 mg, 
0.063 mmol), suspended in MeOH (3 mL), was added sodium 
borohydride (24 mg, 0.64 mmol) and paraformaldehyde (36 mg, 
1.2 mmol). After TFA (0.6 mL) was added dropwise, the reaction 
mixture was stirred under an inert atmosphere at ambient 
temperature for 24 h. The reaction mixture was then poured to a 
mixture of 25% NaOH(aq.) (10 mL) and crushed ice. The pH was 
adjusted to ~11 and the mixture extracted with DCM (3 x 20 
mL). The combined organic layers were dried (Na2SO4) and the 
volatiles removed in vacuo. The crude product was purified by 
preparative HPLC.  
5.1.8.  ter t -Buty l(3-(4 -(( (6-phenoxybenzothiazol -2-
y l)amino)methyl)phenoxy)propyl)carbamate  (10a )
1 7
 
The title compound was synthesized according to general 
procedure A with the thiazole amine 8a (700 mg, 2.89 mmol) and 
the aldehyde 9
17
 (969 mg, 3.47 mmol). Compound 10a was 
obtained as a solid (1.0 g, 68%) after purification by column 
chromatography [30% EtOAc: 70% hexanes].  
Rf: 0.20 (20% EtOAc: 80% hexanes); M.P: 142-144 °C; IR 
(cm
-1
) : 3392, 2977, 1689, 1260, 1174, 1051, 870; 
1
H NMR (400 
MHz, CDCl3): δ 7.50 (d, J = 8.4 Hz, 1H), 7.33–7.27 (complex, 
4H), 7.24 (d, J = 2.4 Hz, 1H), 7.08 (t, J = 7.2 Hz, 1H), 7.02–6.97 
(complex, 3H), 6.89 (d, J = 8.8 Hz, 2H), 4.76 (s, 1H), 4.55 (s, 
2H), 4.02 (t, J = 6.0 Hz, 2H), 3.33 (q, J = 5.6 Hz, 2H), 1.99 (quin, 
J = 5.6 Hz, 2H), 1.44 (s, 9H); 
13
C NMR (100 MHz, CDCl3): δ 
166.6, 158.5, 158.3, 156.0, 151.7, 145.7, 131.4, 129.7, 129.6, 
129.1, 122.7, 119.5, 118.6, 118.0, 114.7, 111.9, 79.3, 65.8, 48.8, 
38.0, 29.5, 28.4; HRMS (ESI): m/z calcd for C28H31N3NaO4S 
(M+Na)
+
 528.1927, found 528.1925. 
5.1.9.  N-(4-(3-Aminopropoxy) benzyl) -6-




The title compound was synthesized according to general 
procedure C with 10a (250 mg, 0.495 mmol), DCM (4 mL) and 
sat. HCl in dioxane (2.5 mL) to give the title compound 6a as a 
solid (185 mg, 92%). A small amount was purified by HPLC in 
order to obtain an analytically pure sample.  
Rf: 0.25 (10% MeOH: 90% DCM); M.P: 238–240 °C, IR (cm
-
1
) : 3443, 2920, 1630, 1247, 1022, 872;
 1
H NMR (CD3OD, 400 
MHz): δ 7.46 (d, J = 8.8 Hz, 1H), 7.37-7.32 (complex, 5H), 7.12 
(t, J = 7.2 Hz, 1H), 7.07 (dd, J = 2.4, 8.8 Hz, 1H), 6.99 (d, J = 8.4 
Hz, 4H), 4.60 (s, 2H), 4.13 (t, J = 5.6 Hz, 2H), 3.17 (t, J = 7.2 
Hz, 2H), 2.16 (quin, J = 6.4 Hz, 2H); 
13
C NMR (CD3OD, 100 
MHz): δ 169.3, 160.1, 158.5, 155.9, 137.9, 131.3, 130.7, 129.0, 
127.2, 125.2, 120.4, 119.9, 117.0, 116.2, 113.8, 66.5, 38.7, 28.4; 
19
F NMR (CD3OD, 376 MHz): δ -77.1; HRMS (ESI): m/z calcd 
for C23H24N3O2S (M+H)
+
 406.1584, found 406.1582. 
5.1.10.  2-(3-(4 -(( (6-Phenoxybenzothiazol -2-
y l)amino)methyl)phenoxy)propyl)guanidine  
tr i f luoroacetate  (7a )
1 7
 
The title compound was synthesized according to general 
procedure D, compound 7a was obtained as oil (79%, two steps). 
The intermediate di-Boc protected compound was synthesized 
with 6a (150 mg, 0.370 mmol), N,N′-di-Boc-1H-pyrazole-1-
carboxamidine (115 mg, 0.370 mmol), TEA (0.05 mL, 0.4 mmol) 
and DMF (2 mL). The crude product was purified by column 
chromatography (25% EtOAc: 75% hexanes) to give the 
intermediate as an oil (190 mg, 79%). 
Rf: 0.25 (20% EtOAc: 80% hexanes); IR (cm
-1
): 3324, 2978, 
1724, 1614, 1220, 1137, 1050, 807; 
1
H NMR (CDCl3, 400 MHz): 
δ 11.50 (s, 1H), 8.65 (s, 1H), 7.51 (d, J = 8.8 Hz, 1H), 7.34–7.29 
(complex, 4H), 7.22 (d, J = 2.0 Hz, 1H), 7.10 (t, J = 7.2 Hz, 1H), 
7.05 (dd, J = 2.4 Hz, 8.8 Hz, 1H), 6.99–6.93 (complex, 4H), 4.55 
(s, 2H), 4.06 (t, J = 5.6 Hz, 2H), 3.66 (q, J = 6.0 Hz, 2H), 2.09 
(quin, J = 6.0 Hz, 2H), 1.50 (s, 18H); 
13
C NMR (CDCl3, 125 
MHz): δ 163.7, 158.8, 158.2, 156.3, 153.3, 152.3, 129.9, 129.3, 
123.1, 123.2, 118.8, 118.7, 118.4, 118.3, 115.0, 112.1, 83.2, 79.5, 
66.7, 49.2, 39.3, 28.8, 28.5, 28.3; HRMS (ESI): m/z calcd for 
C34H42N5O6S (M+H)
+
 648.2850, found 648.2848. 
The title compound was synthesized with the bis-Boc 
protected guanylated compound (105 mg, 0.162 mmol), EtOH (3 
mL) and acetyl chloride (0.93 mL, 12.98 mmol). The title 
compound was obtained as a sticky solid (80 mg, quant.). A 
small amount was purified by HPLC in order to obtain an 
analytically pure sample.  
Rf: 0.18 (10% MeOH: 90% DCM); M.P: 171–174 °C; IR (cm
-
1
): 3339, 1627, 1328, 1126, 935, 737; 
1
H NMR (CD3OD, 500 
MHz): δ 7.57 (d, J = 8.5 Hz, 1H), 7.46 (d, J = 2.0 Hz, 1H), 7.41–
7.37 (complex, 4H), 7.19–7.14 (complex, 2H), 7.02 (d, J = 8.0 
Hz, 4H), 4.68 (s, 2H), 4.09 (t, J = 5.5 Hz, 2H), 3.41 (t, J = 6.5 
Hz, 2H), 2.08 (quin, J = 6.5 Hz, 2H); 
13
C NMR (CD3OD, 125 
MHz): δ 160.6, 159.9, 159.2, 158.9, 158.8, 154.4, 131.2, 131.1, 
130.5, 130.4, 124.5, 120.2, 119.8, 119.7, 119.4, 118.4, 116.1, 
115.9, 113.4, 66.2, 39.8, 39.7, 29.7; 
19
F NMR (CD3OD, 376 
MHz): δ -77.1; HRMS (ESI): m/z calcd for C24H26N5O2S (M+H)
+
 
448.1802, found 448.1802. 
5.1.11.  ter t -Buty l  (3-(4 -((methyl(6-
phenoxybenzothiazol -2-
y l)amino)methyl)phenoxy)propyl)carbamate  (11a )  
The title compound was synthesized according to general 
procedure B with 10a (200 mg, 0.396 mmol), dry THF (4 mL), 
  
NaH (33 mg, 0.87 mmol) and MeI (67 mg, 0.48 mmol). After 
column chromatography purification [25% EtOAc: 75% hexanes] 
compound 11a was obtained as a semi-solid (195 mg, 95%). 
Rf: 0.29 (20% EtOAc: 80% hexanes); IR (cm
-1
): 3362, 2954, 
1708, 1490, 1249, 1174, 1048, 757; 
1
H NMR (CDCl3, 500 MHz): 
δ 7.54 (d, J = 8.7 Hz, 1H), 7.32 (t, J = 7.5 Hz, 2H), 7.27 (d, J = 
5.8 Hz, 1H), 7.26 (d, J = 8.7 Hz, 2H), 7.07 (t, J = 7.4 Hz, 1H), 
7.03 (dd, J = 2.5, 8.7 Hz, 1H), 6.99 (d, J = 8.6 Hz, 2H), 6.87 (d, J 
= 8.6 Hz, 2H), 4.80 (br s, 1H), 4.68 (s, 2H), 4.01 (t, J = 6.0 Hz, 
2H), 3.33 (q, J = 6.1 Hz, 2H), 3.10 (s, 3H), 1.98 (t, J = 6.1 Hz, 
2H), 1.44 (s, 9H); 
13
C NMR (CDCl3, 125 MHz): δ 168.5, 158.6, 
158.6, 156.2, 151.2, 149.7, 132.0, 129.8, 129.1, 128.6, 122.8, 
119.5, 118.6, 118.0, 114.8, 112.1, 79.4, 66.0, 56.1, 38.2, 37.7, 
29.7, 28.6; HRMS (ESI): m/z calcd for C29H33N3NaO4S (M+Na)
+
 
542.2084, found 542.2087. 
5.1.12.  N-(4-(3-Aminopropoxy)benzyl) -N-methyl-6-
phenoxybenzothiazol -2-amine  (12a )  
The title compound was synthesized according to general 
procedure C with with 11a (44 mg, 0.085 mmol), DCM (1mL) 
and 1.25 M HCl in MeOH (1 mL). The title compound was 
obtained as cream solid (56 mg, quant.). A small amount was 
purified by HPLC in order to obtain an analytically pure sample.  
Rf: 0.20 (10% MeOH: 90% DCM); IR (cm
-1
): 3422, 2938, 
1625, 1248, 1049, 926, 833; 
1
H NMR (CD3OD, 600 MHz): δ 
7.49 (d, J = 8.7 Hz, 1H), 7.39 – 7.33 (complex, 3H), 7.33 – 7.28 
(complex, 2H), 7.10 (tt, J = 7.4, 1.1 Hz, 1H), 7.03 (dd, J = 8.7, 
2.5 Hz, 1H), 7.00 – 6.95 (complex, 4H), 4.75 (s, 2H), 4.14 (t, J = 
5.7 Hz, 2H), 3.18 (t, J = 7.3 Hz, 2H), 3.15 (s, 3H), 2.16 (m, 2H); 
13
C NMR (CD3OD, 150 MHz): δ 171.2, 160.6, 160.5, 153.8, 
150.9, 133.5, 131.7, 131.1, 130.9, 124.8, 120.7, 120.4, 119.8, 
116.7, 113.8, 67.1, 57.7, 39.5, 39.1, 29.2; 
19
F NMR (CD3OD, 376 
MHz): δ -76.6; HRMS (APCI): m/z calcd for C24H26N3O2S 
(M+H)
+
 420.1740, found 420.1738. 
5.1.13.  2-(3-(4 -((Methyl (6-phenoxybenzothiazol -2-
y l)amino)methyl)phenoxy)propyl)guanidine  
tr i f luoroacetate  (13a )  
The title compound was synthesized according to general 
procedure D, compound 13a was obtained as oil (60%, two 
steps). 
The intermediate di-Boc protected compound was synthesized 
with 12a (200 mg, 0.480 mmol), N,N′-di-Boc-1H-pyrazole-1-
carboxamidine (149 mg, 0.480 mmol), TEA (0.13 mL, 0.95 
mmol) and DMF (5 mL). The crude product was purified by 
column chromatography (20% EtOAc: 80% hexanes) to give the 
intermediate as an oil (190 mg, 58%). 
Rf: 0.32 (30% EtOAc: petroleum ether); IR (cm
-1
): 3334, 
2930, 1722, 1635, 1456, 1136, 1027, 935, 757; 
1
H NMR (CDCl3, 
400 MHz): δ 11.51 (s, 1H), 8.65 (br s, 1H), 7.53 (d, J = 8.4 Hz, 
1H), 7.32 (t, J = 7.6 Hz, 2H), 7.23 (d, J = 8.4 Hz, 2H), 7.07–7.00 
(m, 2H), 6.98 (d, J = 8.0 Hz, 3H), 6.93 (d, J = 8.4 Hz, 2H), 4.67 
(s, 2H), 4.05 (t, J = 5.6 Hz, 2H), 3.64 (q, J = 4.0 Hz, 2H), 3.09 (s, 
3H), 2.07 (quin, J = 6.0 Hz, 2H), 1.49 (s, 18H); 
13
C NMR 
(CDCl3, 100 MHz): δ 168.5, 163.7, 158.6, 158.5, 156.3, 153.3, 
151.2, 149.7, 131.9, 129.8, 129.1, 128.6, 122.8, 119.6, 118.6, 
118.0, 114.9, 112.0, 83.2, 79.4, 66.6, 56.1, 39.2, 37.7, 28.7, 28.4, 
28.3, 28.2; HRMS (ESI): m/z calcd for C35H44N5O6S (M+H)
+
 
662.3007, found 662.3002. 
The title compound was synthesized with the bis-Boc 
protected guanylated compound (190 mg, 0.287 mmol), EtOH (4 
mL) and acetyl chloride (1.8 mL, 23 mmol). The title compound 
was obtained as a solid (125 mg, 97%). A small amount was 
purified by HPLC in order to obtain an analytically pure sample.  
Rf: 0.21 (10% MeOH: 90% DCM); M.P: 161–164 °C; I.R: 
(cm
-1
): 3422, 2938, 1625, 1248, 1049, 926, 
1
H NMR (CD3OD, 
400 MHz): δ 7.53 (d, J = 8.8 Hz, 1H), 7.41 (d, J = 2.4 Hz, 1H), 
7.39–7.34 (complex, 2H), 7.33 (d, J = 8.8 Hz, 2H), 7.15-7.10 
(complex, 2H), 7.02-6.97 (complex, 4H), 4.78 (s, 2H), 4.10 (t, J 
= 6.0 Hz, 2H), 3.43 (t, J = 6.8 Hz, 2H), 3.32 (s, 3H), 2.10 (quin, J 
= 6.4 Hz, 2H); 
13
C NMR (CD3OD, 100 MHz): δ 170.4, 160.3, 
159.4, 154.2, 131.1, 130.4, 129.0, 124.5, 120.1, 119.5, 118.9, 
116.1, 113.4, 66.2, 57.8, 39.7, 38.8, 29.8; 
19
F NMR (CD3OD, 376 
MHz): δ -77.1; HRMS (ESI): m/z calcd for C25H27N5O2S (M+H)
+
 
462.1958, found 462.1962. 
5.1.14.  4-((2- ((4- (3-
Aminopropoxy)benzyl)amino)benzothiazol -6-
y l)oxy)phenol  tr i f luoroacetate  (6b )  
To compound 10b
16
 (50 mg, 0.080 mmol) was added a 
solution of. TFA (0.9 mL) and thioanisole (0.24 mL, 2.0 mmol). 
After the reaction was stirred at ambient temperature, under a 
nitrogen atmosphere, for 1 h the volatiles were removed in vacuo. 
The crude product was triturated with 2:1 (EtOAc: hexanes), 2:1 
(ether: hexanes) and hexanes to remove residual thioanisole. The 
title compound 6b was obtained as a colourless oil (35 mg, 82%). 
A small amount was purified by HPLC in order to obtain an 
analytically pure sample. 
Rf: 0.4 (10% MeOH: 90% DCM); IR (cm
-1
): 3445, 2923, 
1674, 1136, 841, 770; 
1
H NMR (CD3OD, 400 MHz): δ 7.42 (d, J 
= 8.8 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.24 (d, J = 2.4 Hz, 1H), 
7.01–6.96 (complex, 3H), 6.88– 6.77 (complex, 4H), 4.59 (s, 
2H), 4.13 (t, J = 5.6 Hz, 2H), 3.17 (t, J = 7.6 Hz, 2H), 2.15 (quin, 
J = 6.0 Hz, 2H); 
13
C NMR (CD3OD, 100 MHz): δ 169.3, 160.1, 
157.3, 155.4, 150.6, 142.4, 139.3, 130.6, 129.6, 122.0, 118.9, 
117.5, 117.3, 116.1, 112.0, 66.4, 38.7, 28.5; 
19
F NMR (CD3OD, 
376 MHz): δ -76.9; HRMS (ESI): m/z calcd for C23H24N3O3S 
(M+H)
+
 422.1538, found 422.1539.  
5.1.15.  2-(3-(4 -(( (6-(4 -
Hydroxyphenoxy)benzo[d] thiazol -2-
y l)amino)methyl)phenoxy)propyl)gu anidine  
tr i f luoroacetate  (7b )  
The title compound was synthesized according to general 
procedure D, compound 7b was obtained as oil (62%, two steps). 
The intermediate di-Boc protected compound was synthesized 
with 6b (80 mg, 0.15 mmol), N,N′-di-Boc-1H-pyrazole-1-
carboxamidine (48 mg, 0.15 mmol), TEA (0.11 mL, 0.77 mmol) 
and DMF (3 mL). The crude product was purified by column 
chromatography (50% EtOAc: 50% hexanes) to give the 
intermediate as an oil (63 mg, 62%). 
Rf: 0.28 (20% EtOAc: 80% hexanes); IR (cm
-1
): 3322, 2928, 
1726, 1648, 1214, 919, 809; 
1
H NMR (CDCl3, 500 MHz): 11.63 
(s, 1H), 8.81 (s, 1H), 7.40 (s, 4H), 7.03–6.98 (complex, 7H), 4.64 
(s, 2H), 4.12 (br s, 2H), 3.73 (br s, 2H), 2.17 (br s, 2H), 1.62 (s, 
9H), 1.61 (9H); 
13
C NMR (CDCl3, 125 MHz): δ 163.5, 158.8, 
158.7, 156.3, 153.3, 152.7, 152.6, 150.5, 150.3, 129.3, 120.6, 
117.5, 117.4, 116.7, 114.9, 110.5, 83.3, 79.7, 66.6, 39.3, 28.8, 
28.4, 28.3; HRMS (ESI): m/z calcd for C34H41N5O7S (M+H)
+
 
664.2805, found 664.2806. 
The title compound was synthesized with the bis-Boc 
protected guanylated compound (63 mg, 0.095 mmol), EtOH (3 
mL) and acetyl chloride (0.54 mL, 7.6 mmol). The title 
compound was obtained as a sticky colourless solid (50 mg, 
quant.). A little amount was further purified by preparative 
HPLC. 
Rf: 0.22 (10% MeOH: 90% DCM); IR (cm
-1
): 3445, 2923, 
1674, 1136, 841, 770; 
1
H NMR (CD3OD, 400 MHz): δ 7.44 (d, J 
= 8.8 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.26 (d, J = 2.4 Hz, 1H), 
7.04 (dd, J = 2.8, 8.8 Hz, 1H), 6.99 (d, J = 8.8 Hz, 2H), 6.89 (d, J 
= 9.2 Hz, 2H), 6.81 (d, J = 8.8 Hz, 2H), 4.60 (s, 2H), 4.09 (t, J = 
6.0 Hz, 2H), 3.41 (t, J = 7.2 Hz, 2H), 2.09 (quin, J = 6.4 Hz, 2H); 
13
C NMR (CD3OD, 100 MHz): δ 169.1, 160.1, 158.9, 156.5, 
  
155.2, 151.0, 130.5, 130.4, 129.2, 122.1, 121.7, 118.5, 118.1, 
117.5, 117.4, 116.0, 115.2, 112.1, 111.8, 66.2, 39.8, 29.8; 
19
F 
NMR (CD3OD, 376 MHz): δ -76.9; HRMS (ESI): m/z calcd for 
C24H25N5O3S (M)
+
. 463.1678, found 463.1691. 
5.1.16.  4-((2- ((4- (3-ter t -Buty l (3-(4 -(( (6-(4 -
(benzyloxy)phenoxy)benzo[d] thiazol-2-
y l)(methyl)amino)methyl)phenoxy)propyl)carbamate  
(11b )  
The title compound was synthesized according to general 
procedure C, with 10b (200 mg, 0.327 mmol), dry THF (9 mL), 
NaH (28 mg, 0.72 mmol) and MeI (0.02 mL, 0.39 mmol). After 
column chromatography purification [20% EtOAc: 80% 
hexanes], compound 33 was obtained as oil (170 mg, 83%).  
Rf: 0.27 (20% EtOAc: 80% hexanes); IR (cm
-1
): 3322, 2928, 
1726, 1648, 1214, 919, 809; 
1
H NMR (CDCl3, 400 MHz): δ 7.55 
(d, J = 8.8 Hz, 1H), 7.45–7.37 (complex, 4H), 7.35–7.31 
(complex, 1H), 7.24 (d, J = 8.4 Hz, 2H), 7.19 (d, J = 2.4 Hz, 1H), 
7.00 (dd, J = 8.8 Hz, 2.4 Hz, 1H), 6.95 (s, 4H), 6.87 (d, J = 8.4 
Hz, 2H), 5.04 (s, 2H), 4.76 (s, 1H), 4.68 (s, 2H), 4.02 (t, J = 6.0 
Hz, 2H), 3.33 (t, J = 6.0 Hz, 2H), 3.13 (s, 3H), 1.97 (quin, J = 6.0 
Hz, 2H), 1.44 (s, 9H); 
13
C NMR (CDCl3, 125 MHz): δ 168.1, 
158.8, 156.2, 155.0, 151.6, 137.2, 129.3, 128.8, 128.2, 127.7, 
120.1, 119.2, 117.9, 116.1, 114.9, 110.7, 79.4, 70.7, 66.1, 56.7, 
38.2, 38.2, 29.7, 28.6; HRMS (ESI): m/z calcd for C36H40N3O5S 
(M+H)
+
 626.2683, found 626.2686. 
5.1.17.  4-((2- ((4- (3-
Aminopropoxy)benzyl)(methyl)amino)benzo[d] thiaz
ol-6-y l)oxy)phenol  tr i f luoroacetate  (12b ) 
To compound 11b (100 mg, 0.160 mmol) was added a 
solution of TFA (1.8 mL) and thioanisole (0.48 mL, 4.0 mmol). 
After the reaction was stirred at ambient temperature, under a 
nitrogen atmosphere, for 1 h the volatiles were removed in vacuo. 
The crude product was triturated with 2:1 (EtOAc: hexanes), 2:1 
(ether: hexanes) and hexanes to remove residual thioanisole. The 
title compound 12b was obtained as a colourless oil (85 mg, 
quant.). A small amount was purified by HPLC in order to obtain 
an analytically pure sample.  
Rf: 0.42 (10% MeOH: 90% DCM); IR (cm
-1
): 3435, 2925, 
1670, 1076, 840, 770; 
1
H NMR (CD3OD, 400 MHz): δ 7.47 (d, J 
= 8.8 Hz, 1H), 7.32 (d, J = 8.8 Hz, 2H), 7.29 (d, J = 2.4 Hz, 1H), 
7.06 (dd, J = 2.8, 8.8 Hz, 1H), 6.90 (d, J = 8.8 Hz, 2H), 6.89 (d, J 
= 8.8 Hz, 2H), 6.81 (d, J = 8.8 Hz, 2H), 4.76 (s, 2H), 4.13 (t, J = 
6.0 Hz, 2H), 3.23 (s, 3H), 3.17 (t, J = 7.6 Hz, 2H), 2.14 (quin, J = 
6.0 Hz, 2H); 
13
C NMR (CD3OD, 100 MHz): δ 170.1, 160.0, 
155.8, 155.0, 151.3, 131.2, 130.3, 129.6, 121.6, 119.1, 118.8, 
118.6, 117.4, 116.1, 111.5, 66.4, 57.5, 38.8, 38.7, 28.5; 
19
F NMR 
(CD3OD, 376 MHz): δ -77.1; HRMS (ESI): m/z calcd for 
C24H26N3O3S (M+H)
+
 436.1695, found 436.1684. 
5.1.18.  2-(3-(4 -(( (6-(4 -
Hydroxyphenoxy)benzo[d] thiazol -2-
y l)(methyl)amino)methyl)phenoxy)propyl)guanidine  
tr i f luoroacetate  (13b )  
The title compound was synthesized according to general 
procedure D, compound 13b was obtained as oil (35% yield over 
two steps). 
The intermediate di-Boc protected compound was synthesized 
with 12b (95 mg, 0.18 mmol), N,N′-di-Boc-1H-pyrazole-1-
carboxamidine (57 mg, 0.18 mmol), TEA (0.08 mL, 0.5 mmol) 
and DMF (3 mL). The crude product was purified by column 
chromatography (50% EtOAc: 50% hexanes) to give the 
intermediate as an oil (70 mg, 56%).  
Rf: 0.25 (20% EtOAc: 80% hexanes); IR (cm
-1
): 3335, 2920, 
1721, 1640, 1136, 817; 
1
H NMR (CDCl3, 400 MHz): δ 11.49 (s, 
1H), 8.70 (s, 1H), 7.49 (d, J = 8.8 Hz, 1H), 7.20–7.15 (complex, 
3H), 6.94–6.80 (m, 7H), 4.64 (s, 2H), 4.00 (br s, 2H), 3.62 (br s, 
2H), 3.09 (s, 3H), 2.04 (br s, 2H), 1.49 (s, 9H), 1.47 (s, 9H); 
13
C 
NMR (CDCl3, 100 MHz): δ 168.4, 163.4, 158.5, 156.3, 153.2, 
152.7, 150.7, 148.2, 131.4, 129.0, 128.3, 120.3, 119.2, 117.4, 
116.6, 114.8, 110.4, 83.3, 79.7, 66.5, 56.4, 39.9, 37.9, 28.7, 28.4, 
28.2; HRMS (ESI): m/z calcd for C35H43N5O7S (M+H)
+
 
678.2961, found 678.2962. 
The title compound was synthesized with bis-Boc protected 
guanylated compound (70 mg, 0.10 mmol), EtOH (2 mL) and 
acetyl chloride (0.59 mL, 8.3 mmol). The title compound was 
obtained as a colourless oil (35 mg, 62%). A small amount was 
purified by HPLC in order to obtain an analytically pure sample. 
Rf: 0.43 (10% MeOH: 90% DCM); IR (cm
-1
): 3163, 2860, 
1606, 1119, 1049, 824; 
1
H NMR (CD3OD, 400 MHz): δ 7.46 (d, 
J = 8.8 Hz, 1H), 7.31-7.27 (complex, 3H), 7.05 (dd, J = 2.4, 8.8 
Hz, 1H), 6.98 (d, J = 8.8 Hz, 2H), 6.89 (d, J = 9.2 Hz, 2H), 6.80 
(d, J = 8.8 Hz, 2H), 4.75 (s, 2H), 4.08 (t, J = 6.0 Hz, 2H), 3.41 (t, 
J = 7.2 Hz, 2H), 3.20 (s, 3H), 2.07 (quin, J = 6.0 Hz, 2H); 
13
C 
NMR (CD3OD, 100 MHz): δ 170.1, 160.4, 158.9, 156.3, 155.2, 
155.1, 130.4, 130.1, 128.8, 121.7, 118.8, 118.5, 117.4, 116.2, 
111.6, 66.2, 58.0, 39.7, 38.9, 29.8; 
19
F NMR (CD3OD, 376 MHz): 
δ -77.0; HRMS (ESI): m/z calcd for C25H27N5O3S (M)
+
. 
477.1835, found 477.1847. 
5.1.19.  ter t -Buty l  (3-(4 -(( (6-(4 -
f luorophenoxy)benzo[d] thiazol-2-
y l)amino)methyl)phenoxy)propyl)carbamate  (10c ) 
The title compound was synthesized according to general 
procedure A with the thiazole amine 7 (1.2 g, 4.6 mmol) and the 
aldehyde 9
17
 (1.54 g, 5.53 mmol). Compound 10c was obtained 
as a colourless solid. (2.0 g, 77%) 
Rf: 0.43 (20% EtOAc: 80% hexanes); M.P: 145-147 °C, IR 
(cm
-1
): 3433, 2925, 2854, 1630, 1412, 1315, 1263, 1026, 779; 
1
H 
NMR (CDCl3, 400 MHz): δ 7.45 (d, J = 8.7 Hz, 1H), 7.30 (d, J = 
8.6 Hz, 2H), 7.18 (d, J = 2.4 Hz, 1H), 7.02−6.92 (complex, 5H), 
6.86 (d, J = 8.6 Hz, 2H), 4.77 (br s, 1H), 4.53 (s, 2H), 4.01 (t, J = 
6.0 Hz, 2H), 3.31 (q, J = 6.2 Hz, 2H), 1.96 (quin, J = 6.2 Hz, 
2H), 1.43 (s, 9H); 
13
C NMR (CDCl3, 100 MHz): δ 167.0, 159.9 
(d, J = 239.5 Hz), 158.7, 156.2, 154.0, 152.5, 147.6, 131.0, 129.4, 
129.3, 119.9 (d, J = 8.1 Hz), 119.4, 118.1, 116.5 (d, J = 23.3 Hz), 
114.9, 111.5, 79.4, 66.0, 49.1, 38.2, 29.7, 28.6; 
19
F NMR (CDCl3, 
470 MHz): δ -121.3; HRMS (ESI): m/z calcd for 
C28H30FN3NaO4S 546.1833, found 546.1836. 
5.1.20.  N-(4-(3-Aminopropoxy)benzyl) -6-(4-
f luorophenoxy)benzo[d] thiazol -2-amine 
tr i f luoroacetate  (6c )  
The title compound was synthesized according to general 
procedure C with 10c (200 mg, 0.382 mmol), DCM (1 mL) and 
sat. HCl in dioxane (1 mL) to give the title compound 9c as a 
solid (150 mg, 93%). A small amount was purified by HPLC in 
order to obtain an analytically pure sample. 
Rf: 0.21 (10% MeOH: 90% DCM); M.P: 169–171 °C; IR (cm
-
1
): 3417, 1659, 1549, 1500, 1458, 1352, 1205, 1117; 
1
H NMR 
(CD3OD, 400 MHz): δ 7.54 (d, J = 7.2 Hz, 1H), 7.45−7.40 
(complex, 3H), 7.19 (d, J = 9.2 Hz, 1H), 7.15−7.11 (complex, 
2H), 7.08−7.02 (m, 4H), 4.67 (s, 2H), 4.15 (t, J = 6.0 Hz, 2H), 
3.16 (t, J = 6.0 Hz, 2H), 2.16 (quin, J = 6.0 Hz, 2H); 
13
C NMR 
(CD3OD, 125 MHz): δ 169.4, 161.8 (d, J = 239.6 Hz), 160.5, 
156.9, 154.3, 154.3, 135.6, 130.9, 128.3, 126.4, 122.1 (d, J = 7.5 
Hz), 120.3, 117.8 (d, J = 23.5 Hz), 116.3, 113.6, 66.6, 50.6, 38.8, 
28.5; 
19
F NMR (CD3OD, 376 MHz): δ -122.9, -77.1; HRMS 
(ESI): m/z calcd for C23H23FN3O2S 424.1490, found 424.1487.  
5.1.21.  2-(3-(4 -(( (6-(4 -
Fluorophenoxy)benzo[d] thiazol -2 
  
yl)amino)methyl)phenoxy)propyl)guanidine  
tr i f luoroacetate  (7c )  
The title compound was synthesized according to general 
procedure E with 6c (100 mg, 0.236 mmol), 1H-pyrazole-1-
carboxamidine hydrochloride (35 mg, 0.24 mmol), potassium 
carbonate (65 mg, 0.47 mmol) and DMF (1 mL). Purification 
with ammoniacal silica gel, eluting with 10% MeOH: 90% DCM 
gave the title compounds 7c as a solid (80 mg, 76%) which was 
further purified by preparative HPLC.  
Rf: 0.2 (10% MeOH: 90% DCM); M.P: 179–181 °C; IR (cm
-
1
): 3341, 1629, 1331, 1130, 935, 725; 
1
H NMR (CD3OD, 400 
MHz): δ 7.44 (d, J = 8.0 Hz, 1H), 7.35 (d, J = 8.4 Hz, 2H), 7.30 
(d, J = 2.0 Hz, 1H), 7.09 (t, J = 8.8 Hz, 2H), 6.99–6.91 (complex, 
5H), 4.56 (s, 2H), 4.08 (t, J = 6.0 Hz, 2H), 3.41 (t, J = 6.8 Hz, 
2H), 2.08 (quin, J = 6.4 Hz, 2H); 
13
C NMR (DMSO-d6, 125 
MHz): δ 166.9, 159.6 (d, J = 241.1 Hz), 158.5, 157.9, 155.0 (d, J 
= 1.8 Hz), 151.7, 150.0, 132.6, 132.0, 129.7, 120.3 (d, J = 8.5 
Hz), 119.6, 118.3, 117.4 (d, J = 23.1 Hz), 115.3, 113.0, 65.7, 
47.6, 38.8, 29.1; 
19
F NMR (CD3OD, 376 MHz): δ -122.6, -77.0; 




5.1.22.  ter t -Buty l(3-(4 -(( (6-(4 -
f luorophenoxy)benzothiazol -2-
y l)(methyl)amino)methyl)phenoxy)propyl)  
carbamate  (11c ) 
The title compound was synthesized according to general 
procedure B with 10c (150 mg, 0.287 mmol), dry THF (4 mL), 
NaH (27 mg, 0.69 mmol) and MeI (45 mg, 0.32 mmol). After 
column chromatography purification at 25% EtOAc: 75% 
hexanes compound 11c was obtained as a colourless solid (105 
mg, 68%). 
Rf: 0.45 (20% EtOAc: 80% hexanes); M.P: 91–93 °C; IR (cm
-
1
): 3436, 2925, 2854, 1712, 1501, 1203, 1174, 1092, 818; 
1
H 
NMR (CDCl3, 400 MHz): δ 7.54 (d, J = 8.7 Hz, 1H), 7.24 –7.21 
(complex, 3H), 7.02–6.92 (complex, 5H), 6.86 (d, J = 8.6 Hz, 
2H), 4.77 (br s, 1H), 4.67 (s, 2H), 4.01 (t, J = 6.0 Hz, 2H), 3.32 
(q, J = 6.2 Hz, 2H), 3.10 (s, 3H), 1.99 (quin, J = 5.9 Hz, 2H), 
1.43 (s, 9H); 
13
C NMR (CDCl3, 125 MHz,): δ 168.4, 159.6 (d, J = 
239.6 Hz), 158.7, 156.2, 154.3, 151.9, 132.2, 131.8, 129.2, 128.5, 
119.6 (d, J = 8.1 Hz), 119.5, 118.2, 116.4 (d, J = 23.2 Hz), 114.9, 
111.4, 79.4, 66.0, 56.2, 38.2, 37.9, 29.7, 28.6; 
19
F NMR (CDCl3, 
470 MHz): δ -121.3; HRMS (ESI): m/z calcd for C29H33FN3O4S 
(M+H)
+
 538.2170, found 538.2173. 
5.1.23.  N-(4-(3-Aminopropoxy)benzyl) -6-(4-
f luorophenoxy)-N-methylbenzothiazol -2-amine 
tr i f luoroacetate  (12c ) 
The title compound was synthesized according to general 
procedure C with 11c (80 mg, 0.15 mmol), DCM (1 mL) and sat. 
HCl in dioxane (1 mL) to give the title compound 12c as oil (60 
mg, 92%) with purification by trituration using DCM and 
hexanes (1: 10). Further purification by preparative HPLC gave 
an analytically pure sample. 
Rf: 0.23 (10% MeOH: 90% DCM); IR (cm
-1
): 3435, 2925, 
2855, 1624, 1308, 1048, 1024, 816; 
1
H NMR (CD3OD, 400 
MHz): δ 7.49 (d, J = 8.8 Hz, 1H), 7.36 (d, J = 2.4 Hz, 1H), 7.31 
(d, J = 8.4 Hz, 2H), 7.11–6.96 (complex, 7H), 4.75 (s, 2H), 4.13 
(t, J = 6.0 Hz, 2H), 3.18 (s, 3H), 3.17 (t, J = 7.2 Hz, 2H), 2.17 
(quin, J = 6.0 Hz, 2H); 
13
C NMR (CD3OD, 100 MHz): δ 170.5, 
161.4 (d, J = 238.6 Hz), 159.9, 154.0, 148.3, 131.9, 131.9, 130.3, 
129.9, 121.0 (d, J = 8.2 Hz), 119.6, 119.4, 117.5 (d, J = 23.6 Hz), 
116.0, 112.8, 66.4, 57.3, 38.8, 38.6, 28.5; 
19
F NMR (CD3OD, 376 
MHz): δ -122.5, -77.0; HRMS (ESI): m/z calcd for 
C24H25FN3O2S (M+H)
+
 438.1648, found 438.1646. 
5.1.24.  2-(3-(4 -(( (6-(4 -
Fluorophenoxy)benzo[d] thiazol -2- 
y l)(methyl)amino)methyl)phenoxy)propyl)guanidine  
tr i f luoroacetate  (13c ) 
The title compound was synthesized according to general 
procedure D, compound 13c was obtained as oil (59% yield over 
two steps). 
The intermediate di-Boc protected compound was synthesized 
with 12c (110 mg, 0.251 mmol), N,N′-di-Boc-1H-pyrazole-1-
carboxamidine (78 mg, 0.25 mmol), TEA (0.04 mL, 0.3 mmol) 
and DMF (3 mL). The crude product was purified by column 
chromatography (30% EtOAc: 70% hexanes) to give the 
intermediate as a semi-solid (110 mg, 59%). 
Rf: 0.21 (20% EtOAc: 80% hexanes); IR (cm
-1
): 3430, 2925, 
1722, 1618, 1322, 1136, 809; 
1
H NMR (CDCl3, 400 MHz): δ 
11.50 (s, 1H), 8.64 (s, 1H), 7.52 (d, J = 8.5 Hz, 1H), 7.22 (d, J = 
8.5 Hz, 3H), 7.01–6.90 (complex, 7H), 4.67 (s, 2H), 4.05 (t, J = 
5.6 Hz, 2H), 3.65 (q, J = 6.0 Hz, 2H), 3.09 (s, 3H), 2.09 (quin, J 
= 6.0 Hz, 2H), 1.49 (s, 18H); 
13
C NMR (CDCl3, 125 MHz): δ 
168.5, 163.7, 159.5 (d, J = 239.3 Hz), 158.6, 156.3, 154.3 (d, J = 
2.5 Hz), 153.3, 151.7, 149.7, 132.0, 129.1, 128.6, 119.6 (d, J = 
8.3 Hz), 118.1, 116.4 (d, J = 22.9 Hz), 114.8, 111.5, 83.2, 79.4, 
66.6, 56.2, 39.2, 37.7, 28.7, 28.5, 28.3; 
19
F NMR (CDCl3, 470 
MHz): δ -121.3, HRMS (ESI): m/z calcd for C35H42FNaN5O6S 
(M+Na)
+
 702.2732, found 702.2729. 
The title compound was synthesized with bis-Boc protected 
guanylated compound (110 mg, 0.162 mmol), EtOH (2 mL) and 
acetyl chloride (0.93 mL, 13 mmol). The title compound was 
obtained as an oil (80 mg, quant.). A small amount was purified 
by HPLC in order to obtain an analytically pure sample. 
Rf: 0.25 (10% MeOH: 90% DCM); IR (cm
-1
): 3350, 2919, 
1626, 1204, 1048, 758; 
1
H NMR (CD3OD, 400 MHz): δ 7.50 (d, 
J = 8.8 Hz, 1H), 7.38 (d, J = 2.4 Hz, 1H), 7.31 (d, J = 6.4 Hz, 
2H), 7.12–7.06 (complex, 3H), 7.03–6.96 (complex, 4H), 4.76 (s, 
2H), 4.09 (t, J = 6.0 Hz, 2H), 3.42 (t, J = 6.8 Hz, 2H), 3.20 (s, 
3H), 2.09 (quin, J = 6.0 Hz, 2H); 
13
C NMR (CD3OD, 150 MHz): 
δ 170.5, 160.9 (d, J = 238.8 Hz), 160.0, 158.9, 158.9, 155.7 (d, J 
= 2.1 Hz), 153.7, 149.3, 132.4, 130.2, 130.0, 120.9 (d, J = 8.1 
Hz), 119.8, 119.3, 117.4 (d, J = 23.2 Hz), 116.0, 112.8, 66.2, 
57.1, 40.3, 39.8, 38.5, 29.8; 
19
F NMR (CD3OD, 376 MHz): δ -
122.7, -76.9; HRMS (ESI): m/z calcd for C25H27FN5O2S (M+H)+ 
480.1864, found 480.1870. 
5.1.25.  N-(4-(3- (Dimethylamino)propoxy)benzyl) -6-
(4-f luorophenoxy)benzo[d] thiazol-2-amine 
tr i f luoroacetate  (14c ) 
The title compound was synthesized according to general 
procedure F with 20 (20 mg, 0.050 mmol), paraformaldehyde (57 
mg, 1.9 mmol), NaBH4 (38 mg, 1.0 mmol), TFA (0.5 mL) and 
MeOH (2 mL). After purification by HPLC the title compound 
was obtained as a semi-solid (10 mg, 48%). 
Rf: 0.21 (10% MeOH: 90% DCM); 
1
H NMR (CD3OD, 400 
MHz): δ 7.48 (d, J = 8.8 Hz, 1H), 7.38-7.35 (complex, 3H), 7.12-
7.06 (m, 3H), 7.03-6.96 (complex, 4H), 4.61 (s, 2H), 3.35 (m, 
2H), 2.94 (s, 6H), 2.21 (m, 2H); 
13
C NMR (CD3OD, 125 MHz): δ 
169.1, 161.1 (d, J = 238.6 Hz), 159.5, 159.2, 155.6, 154.1, 147.8, 
131.9, 130.3, 120.9 (d, J = 8.1 Hz), 119.3, 119.0, 117.5 (d, J = 
23.4 Hz), 115.8, 112.9, 66.1, 57.0, 43.8, 25.9; 
19
F NMR (376 
MHz, CD3OD): δ -122.4, -76.9; HRMS (APCI): m/z calcd for 
C25H26O2N3FS (M)
+.
 451.1724 found 451.1726. 
5.1.26.  ter t -Buty l(3-(4 -(( (6-(4 -
(tr i f luoromethyl)phenoxy)benzothiazol -2-
y l)amino)methyl)phenoxy)propyl)carbamate  ( 10d )  
The title compound was synthesized according to general 
procedure A with the thiazole amine 8d (400 mg, 1.29 mmol) 
and the aldehyde 9
17
 (432 mg, 1.55 mmol). Compound 10d was 
  
obtained as a solid. (404 mg, 55%) after purification by column 
chromatography [25% EtOAc: hexanes]. 
Rf: 0.23 (35% EtOAc: 65% hexanes); M.P: 170–171 °C; IR 
(cm
-1
): 3334, 2872, 1712, 1680, 1121, 911, 741; 
1
H NMR 
(CDCl3, 500 MHz): δ 7.55 (d, J = 8.4 Hz, 2H), 7.48 (dd, J = 1.2 
Hz, 8.8 Hz, 1H), 7.31 (d, J = 8.4 Hz, 2H), 7.28 (d, J = 2.4 Hz, 
1H), 7.01 (dd, J = 2.0, 8.4 Hz, 3H), 6.88 (d, J = 8.8 Hz, 2H), 4.55 
(s, 2H), 4.02 (t, J = 6.0 Hz, 2H), 3.34 (q, J = 6.0 Hz, 2H), 1.99 
(quin, J = 6.0 Hz, 2H), 1.43 (s, 9H); 
13
C NMR (CDCl3, 100 
MHz): δ 167.3, 161.6, 158.7, 156.2, 150.2, 149.7, 131.8, 129.6, 
129.3, 127.3 (q, J = 3.8 Hz), 125.7 (q, J = 269.8 Hz), 124.8 (q, J 
= 32.5 Hz), 119.8, 119.2, 117.3, 114.9, 113.1, 79.5, 66.0, 49.0, 
38.2, 29.7, 28.6; 
19
F NMR (CDCl3, 470 MHz): δ -61.7; HRMS 
(ESI): m/z calcd for C29H31F3N3O4S (M+H)
+
 574.1987, found 
574.1971. 
5.1.27.  N-(4-(3-Aminopropoxy)benzyl) -6-(4-
(tr i f luoromethyl)phenoxy)benzothiazol -2-amine  
tr i f luoroacetate  (6d )  
The title compound was synthesized according to general 
procedure C with 10d (150 mg, 0.262 mmol), DCM (3 mL) and 
sat. HCl in dioxane (1.5 mL) to give the title compound 6d as a 
solid (140 mg, 96%) after trituration DCM: hexanes (1: 10). A 
small amount was purified by HPLC in order to obtain an 
analytically pure sample. 
Rf: 0.19 (10% MeOH: 90% DCM); M.P: 235–237 °C; IR (cm
-
1
): 3431, 2921, 1648, 1333, 1106, 805; 
1
H NMR (CD3OD, 400 
MHz): δ 7.64 (d, J = 8.8 Hz, 2H), 7.51 (d, J = 8.8 Hz, 1H), 7.45 
(d, J = 2.4 Hz, 1H), 7.37 (d, J = 8.8 Hz, 2H), 7.11–7.07 (m, 3H), 
6.98 (d, J = 8.8 Hz, 2H), 4.60 (s, 2H), 4.13 (t, J = 6.0 Hz, 2H), 
3.17 (t, J = 7.2 Hz, 2H), 2.17 (quin, J = 6.0 Hz, 2H); 
13
C NMR 
(CD3OD, 125 MHz): δ 169.7, 162.1, 160.4, 154.6, 137.2, 130.9, 
128.7 (q, J = 3.8 Hz), 128.4, 126.8, 126.6 (q, J = 32.5 Hz), 125.8 
(q, J = 268.4 Hz), 121.7, 119.4, 116.9, 116.3, 115.7, 66.6, 50.6, 
38.8, 28.6; 
19
F NMR (CD3OD, 376 MHz): δ -77.0, -63.2; HRMS 
(ESI): m/z calcd for C24H23F3N3O2S (M+H)
+
 474.1463, found 
474.1457. 
5.1.28.  2-(3-(4 -(( (6-(4 -
(Tr i f luoromethyl)phenoxy)benzothiazol -2-
y l)amino)methyl)phenoxy)propyl)guanidine  
tr i f luoroacetate  (7d )  
The title compound was synthesized according to general 




lesterguanidine was synthesized with 6d (100 mg, 0.196 mmol), 
N, N′-di-Boc-1H-pyrazole-1-carboxamidine (61 mg, 0.20 mmol), 
TEA (0.03 mL, 0.2 mmol) and DMF (2 mL). The crude product 
was purified by column chromatography (25% EtOAc: 75% 
hexanes) to give the intermediate as an oil (90 mg, 64%). 
Rf: 0.22 (25% EtOAc: 75% hexanes); IR (cm
-1
): 3322, 2931, 
1724, 1635, 1137, 810, 759; 
1
H NMR (CDCl3, 500 MHz): δ 
11.50 (s, 1H), 8.64 (s, 1H), 7.54 (d, J = 8.0 Hz, 2H), 7.43 (d, J = 
8.0 Hz, 1H), 7.30 (d, J = 8.0 Hz, 2H), 7.00–6.92 (complex, 6H), 
4.54 (s, 2H), 4.02 (br s, 2H), 3.61 (q, J = 5.5 Hz, 2H), 2.05 (t, J = 
5.5 Hz, 2H), 1.48 (s, 18H); 
13
C NMR (CDCl3, 125 MHz): δ 
167.5, 163.7, 161.4, 158.8, 156.3, 153.3, 150.5, 129.3, 128.7, 
128.5, 127.3 (q, J = 3.6 Hz), 125.4 (q, J = 269.4 Hz), 124.9 (q, J 
= 31.6 Hz), 124.7, 119.5, 119.3, 117.4, 115.0, 113.1, 83.2, 79.5, 
66.6, 49.2, 39.2, 29.9, 28.8, 28.5, 28.3; 
19
F NMR (CDCl3, 470 
MHz): δ -61.7; HRMS (ESI): m/z calcd for C35H41F3N5O6S 
(M+H)
+
 716.2730, found 716.2704. 
The title compound was synthesized with the bis-Boc 
protected guanylated compound (90 mg, 0.12 mmol), EtOH (2 
mL) and acetyl chloride (0.68 mL, 9.5 mmol). The title 
compound was obtained as a solid (60 mg, 94%) after trituration 
with DCM and hexanes (1: 10). A small amount was purified by 
HPLC in order to obtain an analytically pure sample. 
Rf: 0.22 (10% MeOH: 90% DCM); M.P: 195–197 °C; IR (cm
-
1
) : 3412, 2919, 1642, 1177, 804; 
1
H NMR (CD3OD, 400 MHz): 
δ 7.64 (d, J = 8.4 Hz, 2H), 7.52 (d, J = 8.8 Hz, 1H), 7.45 (d, J = 
2.4 Hz, 1H), 7.36 (d, J = 8.8 Hz, 1H), 7.12-7.08 (complex, 3H), 
6.97 (d, J = 8.8 Hz, 2H), 4.60 (s, 2H), 4.09 (t, J = 6.0 Hz, 2H), 
3.42 (t, J = 6.8 Hz, 2H), 2.09 (quin, J = 6.0 Hz, 2H); 
13
C NMR 
(CD3OD, 100 MHz): δ 169.5, 162.0, 160.6, 158.9, 154.6, 136.8, 
131.0, 128.7 (q, J = 3.7 Hz), 128.1, 127.1 (q, J = 266.0 Hz) 
126.7, 126.6 (q, J = 35.5 Hz), 126.4, 121.8, 119.4, 116.8, 115.7, 
66.3, 50.6, 39.8, 29.8; 
19
F NMR (CD3OD, 376 MHz): δ -79.6, -




5.1.29.  ter t -Buty l(3-(4 -((methyl(6- (4-
(tr i f luoromethyl)phenoxy)benzothiazol -2-
y l)amino)methyl)phenoxy)propyl)carbamate  ( 11d )  
The title compound was synthesized according to general 
procedure B with 10d (190 mg, 0.330 mmol), dry THF (10 mL), 
NaH (28 mg, 0.73 mmol) and MeI (56 mg, 0.40 mmol). After 
column chromatography purification [20% EtOAc: 80% hexanes] 
compound 11d was obtained as a solid (130 mg, 77%).  
Rf: 0.25 (35% EtOAc: 65% hexanes); M.P: 98–100 °C; IR 
(cm
-1
): 3420, 2929, 1706, 1122, 760; 
1
H NMR (CDCl3, 400 
MHz): δ 7.57 (t, J = 8.4 Hz, 3H), 7.31 (d, J = 2.4 Hz, 1H), 7.24 
(d, J = 8.8 Hz, 2H), 7.04–7.00 (complex, 3H), 6.87 (d, J = 8.8 
Hz, 2H), 4.79 (s, 1H), 4.69 (s, 2H), 4.02 (t, J = 6.0 Hz, 2H), 3.33 
(q, J = 6.0 Hz, 2H), 3.11 (s, 3H), 1.98 (quin, J = 6.0 Hz, 2H), 
1.43 (s, 9H); 
13
C NMR (CDCl3, 125 MHz): δ 168.8, 161.7, 
158.7, 156.2, 150.2, 149.7, 132.0, 129.2, 128.4, 127.2 (q, J = 3.6 
Hz), 125.6 (q, J = 269.8 Hz), 124.7 (q, J = 32.5 Hz), 119.7, 
119.2, 117.2, 114.9, 112.9, 79.4, 66.0, 56.2, 38.2, 37.9, 29.7, 
28.6; 
19
F NMR (CDCl3, 470 MHz,): δ -61.6; HRMS (ESI): calcd 
for C30H33F3N3O4S (M+H)
+
 588.2144, found 588.2155.  
5.1.30.  N-(4-(3-Aminopropoxy)benzyl) -N-methyl -6-
(4-(tr i f luoromethyl)phenoxy)benzo[d] thiazol -2-
amine  tr i f luoroacetate  (12d ) 
The title compound was synthesized according to general 
procedure C with 11d (120 mg, 0.204 mmol), DCM (3 mL) and 
sat. HCl in dioxane (1.5 mL). The title compound 12d was 
obtained as an oil (95 mg, 92%). A small amount was purified by 
HPLC in order to obtain an analytically pure sample. 
Rf: 0.22 (10% MeOH: 90% DCM); IR (cm
-1
) : 3408, 2925, 
1627, 1066, 766; 
1
H NMR (CD3OD, 400 MHz): δ 7.63 (d, J = 8.8 
Hz, 2H), 7.54 (d, J = 8.8 Hz, 1H), 7.46 (d, J = 2.4 Hz, 1H), 7.30 
(d, J = 8.4 Hz, 2H), 7.10-7.06 (complex, 3H), 6.97 (d, J = 8.8 Hz, 
2H), 4.75 (s, 2H), 4.13 (t, J = 6.0 Hz, 2H), 3.17-3.13 (complex, 
5H), 2.17 (quin, J = 6.0 Hz, 2H); 
13
C NMR (CD3OD, 100 MHz): 
δ 170.8, 163.3, 159.9, 151.4, 150.7, 132.8, 130.3, 130.2, 128.4 (q, 
J = 3.5 Hz), 127.3 (q, J = 266.2 Hz), 125.8 (q, J = 32.2 Hz), 
120.5, 120.2, 118.4, 116.0, 114.4, 66.4, 57.1, 38.8, 38.5, 28.5; 
19
F 
NMR (CD3OD, 376 MHz): δ -76.8, -63.2; HRMS (ESI): calcd 
for C25H24F3N3O2S (M+H)
+
 488.1620, found 488.1638. 
5.1.31.  2-(3-(4 -((Methyl (6-(4-
(tr i f luoromethyl)phenoxy)benzo[d] thiazol -2-
y l)amino)methyl)phenoxy)propyl)guanidine  
tr i f luoroacetate  (13d )  
The title compound was synthesized according to general 
procedure D, compound 13d was obtained as oil (39%, two 
steps). 
The intermediate di-Boc protected compound was synthesized 
with 12d (80 mg, 0.16 mmol), N,N′-di-Boc-1H-pyrazole-1-
carboxamidine (51 mg, 0.16 mmol), TEA (0.02 mL, 0.2 mmol) 
  
and DMF (2 mL). The crude product was purified by column 
chromatography (20% EtOAc: 80% hexanes) to give the 
intermediate as a semi-solid (55 mg, 49%). 
Rf: 0.25 (25% EtOAc: 75% hexanes) IR (cm
-1
): 3337, 2926, 
1725, 1633, 1137, 759; 
1
H NMR (CDCl3, 400 MHz): δ 11.50 (s, 
1H), 8.64 (s, 1H), 7.57–7.54 (m, 3H), 7.31 (d, J = 2.4 Hz, 1H), 
7.24 (d, J = 8.4 Hz, 2H), 7.04–7.00 (complex, 3H), 6.93 (d, J = 
8.4 Hz, 2H), 4.69 (s, 2H), 4.06 (t, J = 5.6 Hz, 2H), 3.66 (q, J = 
5.6 Hz, 2H), 3.11 (s, 3H), 2.09 (quin, J = 5.6 Hz, 2H), 1.50 (s, 
18H); 
13
C NMR (CDCl3, 125 MHz): δ 168.9, 163.7, 161.7, 158.6, 
156.3, 153.3, 150.6, 149.6, 132.2, 129.1, 128.5, 127.2 (q, J = 3.4 
Hz), 125.5 (q, J = 268.7 Hz), 124.6 (q, J = 32.2 Hz), 119.7, 
119.2, 117.2, 114.9, 113.0, 83.2, 79.5, 66.6, 56.2, 39.2, 37.8, 
28.8, 28.5, 28.3; 
19
F NMR (CDCl3, 470 MHz,): δ -61.7; HRMS 
(ESI): m/z calcd for C36H43F3N5O6S (M+H)
+
 730.2886, found 
730.2859. 
The title compound was synthesized with the bis-Boc 
protected guanylated compound (60 mg, 0.08 mmol), EtOH (3 
mL) and acetyl chloride (0.47 mL, 6.6 mmol). The title 
compound was obtained as a solid (41 mg, 80%). A small 
amount was purified by HPLC in order to obtain an analytically 
pure sample. 
Rf: 0.24 (10% MeOH: 90% DCM); IR (cm
-1
): 3337, 2926, 
1725, 1633, 1137, 759; 
1
H NMR (CD3OD, 400 MHz): δ 7.64 (d, 
J = 8.4 Hz, 2H), 7.55 (d, J = 8.8 Hz, 1H), 7.48 (d, J = 2.4 Hz, 
1H), 7.30 (d, J = 8.8 Hz, 2H), 7.13 (dd, J = 2.4, 8.8 Hz, 1H), 7.09 
(d, J = 8.4 Hz, 2H), 4.75 (s, 2H), 4.08 (t, J = 6.0 Hz, 2H), 3.41 (t, 
J = 7.2 Hz, 2H), 3.18 (s, 3H), 2.07 (quin, J = 6.0 Hz, 2H); 
13
C 
NMR (CD3OD, 100 MHz): δ 170.8, 163.2, 160.1, 158.9, 151.5, 
150.2, 132.5, 130.2, 129.8, 128.4 (q, J = 3.8 Hz), 127.2 (q, J = 
268.6 Hz), 125.8 (q, J = 32.4 Hz), 120.5, 120.0, 118.4, 116.0, 
114.4, 66.2, 57.2, 39.7, 38.5, 29.8; 
19
F NMR (CD3OD, 376 
MHz): δ -77.1, -63.2; HRMS (ESI): m/z calcd for C26H27F3N5O2S 
(M+H)
+ 
530.1832, found 530.1829.  
5.1.32.  N-(4-(3- (Dimethylamino)propoxy)benzyl) -N-
methyl-6-(4-(tr i f luoromethyl)phenoxy)benzo[d]  
thiazol-2-amine tr i f luoroacetate  (15d )  
The title compound was synthesised according to the general 
procedure F with 6d (33.4 mg, 0.07 mmol), dry THF (10 mL), 
paraformaldehyde (78 mg, 2.6 mmol), NaBH4 (60 mg, 1.6 mmol) 
and TFA (1.0 mL) and the reaction mixture stirred for 48 h. After 
purification by HPLC the title compound was obtained as an oil 
(34 mg, quant.). A small amount was purified by HPLC in order 
to obtain an analytically pure sample. 
Rf: 0.26 (10% MeOH: 90% DCM); IR (cm
-1
): 2976, 2903, 
2360, 2175, 2155, 1678, 1610, 1454, 1326, 1203, 1140, 1066, 
842, 801, 726, 683, 656; 
1
H NMR (CD3OD, 600 MHz): δ 7.65 (d, 
J = 8.7 Hz, 2H), 7.55 (d, J = 8.7 Hz, 1H), 7.48 (d, J = 2.5 Hz, 
1H), 7.34 – 7.30 (complex, 2H), 7.13 – 7.08 (complex, 3H), 7.00 
– 6.96 (complex, 2H), 4.77 (s, 2H), 4.13 (t, J = 5.8 Hz, 2H), 3.37 
(m, 2H), 3.18 (s, 3H), 2.96 (s, 6H), 2.23 (m, 2H); 
13
C NMR 
(CD3OD, 150 MHz) δ 170.7, 163.1, 159.7, 151.4, 150.0, 132.4, 
130.1, 130.1, 129.7, 128.3 (q, J = 3.9 Hz), 125.4, 120.4, 119.9, 
118.32, 118.29, 115.88, 115.86, 115.4, 114.3, 66.0, 57.0, 56.9, 
43.6, 38.4, 25.8. 
19
F NMR (CD3OD, 376 MHz): δ -77.3, -63.2; 




5.1.33.   (3-{4-[ (6- (3-
Tr i f luoromethylphenoxy)benzothiazol -2-
y lamino)methyl]phenoxy}propyl) -carbamic  acid 
ter t -buty l  es ter  (10e ) 
The title compound was synthesized according to general 
procedure A with the thiazole amine 8e (350 mg, 1.13 mmol) and 
the aldehyde 9
17
 (378 mg, 1.35 mmol). Compound 10e was 
obtained after purification by column chromatography [20% 
EtOAc: 80% hexanes] as a solid (450 mg, 61%). 
Rf: 0.40 (25% EtOAc: 75% hexanes); M.P: 166–168 °C; IR 
(cm
-1
): 3384, 3010, 2879, 1676, 1171, 1022, 757; 
1
H NMR 
(CDCl3, 400 MHz): δ 7.49 (d, J = 8.7 Hz, 1H), 7.43 (t, J = 7.9 
Hz, 1H), 7.32 (d, J = 8.6 Hz, 3H), 7.27 (s, 1H), 7.20 (s, 1H), 7.13 
(dd, J = 2.1, 8.7 Hz, 1H), 7.03 (dd, J = 8.7, 2.4 Hz, 1H), 6.89 (dt, 
J = 2.8, 9.6 Hz, 2H), 4.76 (br s, 1H), 4.56 (s, 2H), 4.02 (t, J = 3.5 
Hz, 2H), 3.34 (q, J = 6.1 Hz, 2H), 1.99 (quin, J = 6.2 Hz, 2H), 
1.44 (s, 9H); 
13
C NMR (CDCl3, 100 MHz): δ 167.2, 158.7, 158.6, 
156.0, 150.7, 148.1, 132.8, 132.4 (q, J = 33.9 Hz), 131.0, 130.3, 
129.2, 129.1, 125.1 (q, J = 270.8 Hz), 120.8, 119.4, 119.3 (q, J = 
3.7 Hz), 118.8, 114.8, 114.5 (q, J = 3.7 Hz), 112.6, 79.3, 65.9, 
49.0, 38.0, 29.5, 28.4; 
19
F NMR (CDCl3, 470 MHz): δ -62.7; 
HRMS: m/z calcd for C29H31F3N3O4S (M+H)
+
 574.1982, found 
574.1986. 
5.1.34.  N-(4-(3-Aminopropoxy)benzyl) -6-(3-
(tr i f luoromethyl)phenoxy)benzothiazol -2-amine (6e)  
The title compound was synthesized according to general 
procedure C with 10e (100 mg, 0.174 mmol), DCM (2 mL) and 
sat. HCl in dioxane (1 mL) to give the title compound 6e as a 
solid (75 mg, 90%). A small amount was purified by HPLC in 
order to obtain an analytically pure sample. 
Rf: 0.20 (10% MeOH: 90% DCM); M.P: 142–144 °C; IR (cm
-
1
): 3163, 2860, 1606, 1119, 1049, 824; 
1
H NMR (CD3OD, 400 
MHz): δ 7.60 ( d, J = 8.8 Hz, 2H), 7.57 (d, J = 2.4 Hz, 1H), 7.46 
(d, J = 7.6 Hz, 1H), 7.42 (d, J = 8.4 Hz, 2H), 7.28-7.25 (complex, 
3H), 7.04 (d, J = 8.8 Hz, 2H), 4.69 (s, 2H), 4.51 (t, J = 6.0 Hz, 
2H), 3.18 (t, J = 7.2 Hz, 2H), 2.19 (quin, J = 6.0 Hz, 2H); 
13
C 
NMR (CD3OD, 100 MHz): δ 169.6, 160.4, 159.7, 152.5, 147.7, 
133.5 (q, J = 32.3 Hz), 132.8, 132.1, 131.4, 130.3, 126.7 (q, J = 
269.9 Hz), 122.2, 120.5 (q, J = 3.8 Hz), 120.1, 119.3, 115.9, 
115.4 (q, J = 3.8 Hz), 114.3, 66.4, 38.8, 28.5; 
19
F NMR (CD3OD, 
376 MHz): δ -76.9, -64.3; HRMS (ESI): calcd for C24H23F3N3O2S 
(M+H)
+
 474.1458, found 474.1455. 
5.1.35.  2-(3-(4 -(( (6-(3 -
(Tr i f luoromethyl)phenoxy)benzothiazol -2-
y l)amino)methyl)phenoxy)propyl)guanidine  ( 7e ) 
The title compound was synthesized according to general 
procedure D, compound 7e was obtained as oil (39%, two steps). 
The intermediate di-Boc protected compound was synthesized 
with 6e (100 mg, 0.196 mmol), N,N′-di-Boc-1H-pyrazole-1-
carboxamidine (61 mg, 0.20 mmol), TEA (0.08 mL, 0.6 mmol) 
and DMF (2 mL). The crude product was purified by column 
chromatography (20% EtOAc: 80% hexanes) to give the 
intermediate as a semi-solid (90 mg, 78%). 
Rf: 0.28 (25% EtOAc: 75% hexanes); M.P: 63–65 °C; IR (cm
-
1
): 3335, 2931, 1730, 1635, 810; 
1
H NMR (CDCl3, 400 MHz): δ 
11.51 (s, 1H), 8.66 (t, J = 4.8 Hz, 1H), 7.45–7.38 (complex, 2H), 
7.31–7.29 (complex, 3H), 7.26 (d, J = 2.4 Hz, 1H), 7.19 (s, 1H), 
7.13 (dd, J = 2.1 Hz, 8.2 Hz, 1H), 7.00 (dd, J = 2.5 Hz, 8.7 Hz, 
1H), 6.94 (d, J = 8.7 Hz, 2H), 4.55 (s, 2H), 4.04 (t, J = 5.7 Hz, 
2H), 3.64 (q, J = 6.3 Hz, 2H), 2.08 (quin, J = 5.8 Hz, 2H), 1.49 
(s, 18H); 
13
C NMR (CDCl3, 100 MHz): δ 167.5, 163.7, 159.0, 
158.7, 156.3, 153.3, 150.6, 131.7, 130.4, 129.5, 128.6, 124.3 (q, J 
= 265.8 Hz), 123.4 (d, J = 23.2 Hz), 120.8, 120.6, 119.7, 119.3, 
118.9, 114.9, 114.6 (q, J = 3.7 Hz), 112.7, 83.2, 79.4, 66.6, 49.1, 
39.2, 28.7, 28.5, 28.2; 
19
F NMR (CDCl3, 376 MHz,): δ -62.8; 




The title compound was synthesized with the bis-Boc 
protected guanylated compound (90 mg, 0.12 mmol), EtOH (2 
mL) and acetyl chloride (0.68 mL, 9.5 mmol). The title 
compound was obtained as a solid (55 mg, 88%) after trituration 
  
with hexanes and diethyl ether. A small amount was purified by 
HPLC in order to obtain an analytically pure sample.  
Rf: 0.32 (10% MeOH: 90% DCM); M.P: 180–182 °C; IR (cm
-
1
): 3354, 2855, 1634, 1329, 1125, 940, 824; 
1
H NMR (CD3OD, 
400 MHz): δ 7.54–7.50 (complex, 2H), 7.46 (d, J = 2.4 Hz, 1H), 
7.40-7.35 (complex, 3H), 7.22–7.21 (complex, 2H), 7.14 (dd, J = 
8.8, 2.4 Hz, 1H), 6.98 (d, J = 8.8 Hz, 2H), 4.61 (s, 2H), 4.09 (t, J 
= 6.0 Hz, 2H), 3.42 (t, J = 6.8 Hz, 2H), 2.09 (quin, J = 6.4 Hz, 
2H); 
13
C NMR (CD3OD, 125 MHz): δ 169.6, 160.6, 159.4, 159.0, 
158.9, 158.8, 155.1, 136.6, 133.9 (q, J = 32.4 Hz), 132.4, 130.9, 
128.1, 126.7, 126.3 (q, J = 270.1 Hz), 123.1, 121.4 (q, J = 3.8 
Hz), 121.3, 116.8, 116.3, 116.2 (q, J = 3.8 Hz),115.2, 66.4, 50.7, 
39.8, 29.8; 
19
F NMR (CD3OD, 376 MHz): δ -76.9, -64.3; HRMS 
(ESI): calcd for C25H25F3N5O2S (M+H)
+
 516.1676, found 
516.1673. 
5.1.36.  ter t -Buty l(3-(4 -((methyl(6- (3-
(tr i f luoromethyl)phenoxy)benzo[d] thiazol -2-
y l)amino)methyl)phenoxy)propyl)carbamate  ( 11e ) 
The title compound was synthesized according to general 
procedure B with 10e (100 mg, 0.174 mmol), dry THF (4 mL), 
NaH (15 mg, 0.38 mmol) and MeI (27 mg, 0.19 mmol). After 
column chromatography purification [40% EtOAc: 60% hexanes] 
compound 11e was obtained as a solid (75 mg, 74%).  
Rf: 0.51 (30% EtOAc: 70% hexanes); M.P: 84–86 °C; IR (cm
-
1
): 3361, 2930, 1705, 1601, 1168, 1049, 932; 
1
H NMR (CDCl3, 
400 MHz): δ 7.58 (dd, J = 3.5 Hz, 8.7 Hz, 1H), 7.42 (t, J = 7.9 
Hz, 1H), 7.29 (d, J = 2.5 Hz, 2H), 7.25 (d, J = 8.4 Hz, 2H), 7.20 
(s, 1H), 7.13 (d, J = 11.2 Hz, 1H), 7.03 (dd, J = 2.2 Hz, 8.7 Hz, 
1H), 6.87 (d, J= 8.4 Hz, 2H), 4.78 (s, 1H), 4.69 (s, 2H), 4.01 (t, J 
= 5.9 Hz, 2H), 3.32 (q, J = 5.9 Hz, 2H), 3.12 (s, 3H), 1.98 (quin, 
J = 5.9 Hz, 2H), 1.43 (s, 9H); 
13
C NMR (CDCl3, 100 MHz): δ 
168.8, 159.2, 158.7, 158.3, 156.2, 153.7, 150.1, 132.4 (q, J = 32.1 
Hz), 132.1, 130.4, 129.2, 128.5, 125.2 (q, J = 266.7 Hz), 120.8, 
119.7, 119.2 (d, J = 4.5 Hz), 119.0, 114.9, 114.4, 112.6, 79.4, 
66.0, 56.2, 38.2, 37.9, 29.7, 28.6; 
19
F NMR (CDCl3, 470 MHz,): 
δ -62.7; HRMS (ESI): m/z calcd for C30H33F3N3O4S (M+H)
+
 
588.2135, found 588.2138. 
5.1.37.  N-(4-(3-Aminopropoxy)benzyl) -N-methyl-6-
(3-(tr i f luoromethyl)phenoxy)benzo[d] thiazol -2-
amine  tr i f luoroacetate  (12e ) 
The title compound was synthesized according to general 
procedure C with 11e (210 mg, 0.426 mmol), DCM (4 mL) and 
sat. HCl in dioxane (2.5 mL). The title compound 12e was 
obtained as a solid (200 mg, quant.). A small amount was 
purified by HPLC in order to obtain an analytically pure sample. 
Rf: 0.19 (10% MeOH: 90% DCM); M. P: 71–74 °C; IR (cm
-1
): 
3433, 2925, 1450, 1328, 1127, 1064, 817; 
1
H NMR (CD3OD, 400 
MHz): δ 7.57–7.52 (complex, 2H), 7.48 (d, J = 2.4 Hz, 1H), 7.40 
(d, J = 7.6 Hz, 1H), 7.32 (d, J = 8.4 Hz, 2H), 7.23-7.21 (complex, 
2H), 7.14 (dd, J = 2.4, 8.4 Hz, 1H), 6.99 (d, J = 8.8 Hz, 2H), 4.77 
(s, 2H), 4.13 (t, J = 6.0 Hz, 2H), 3.21 (s, 3H), 3.17 (t, J = 7.6 Hz, 
2H), 2.18 (quin, J = 6.0 Hz, 2H); 
13
C NMR (CD3OD, 100 MHz): 
δ 170.8, 160.7, 159.9, 151.9, 150.2, 133.5 (q, J = 32.3 Hz), 132.6, 
132.0, 130.3, 130.1, 126.8 (q, J = 270.4 Hz), 122.1, 120.4 (q, J = 
3.9 Hz), 120.2, 120.0, 116.0, 115.2 (q, J = 4.1 Hz), 114.1, 66.4, 
57.1, 38.8, 38.5, 28.5, 
19
F NMR (CD3OD, 376 MHz): δ -76.8, -
64.3; HRMS (ESI): m/z calcd for C25H25F3N3O2S (M+H)
+
 
488.1620, found 488.1614. 
5.1.38.  2-(3-(4 -((Methyl (6-(3-
(tr i f luoromethyl)phenoxy)benzo[d] thiazol -2-
y l)amino)methyl)phenoxy)propyl)guanidine  
tr i f luoroacetate  (13e ) 
The title compound was synthesized according to general 
procedure D, compound 13e was obtained as oil (50%, two 
steps). 
The intermediate di-Boc protected compound was synthesized 
with 12e (100 mg, 0.205 mmol), N,N′-di-Boc-1H-pyrazole-1-
carboxamidine (64 mg, 0.21 mmol), TEA (0.03 mL, 0.2 mmol) 
and DMF (2 mL). The crude product was purified by column 
chromatography (30% EtOAc: 70% hexanes) to give the 
intermediate as an oil (75 mg, 50%). 
Rf: 0.48 (30% EtOAc: 70% hexanes); IR (cm
-1
): 3331, 2930, 
1722, 1614, 1328, 1134, 1026, 810; 
1
H NMR (CDCl3, 400 MHz): 
δ 11.51 (s, 1H), 8.67 (t, J = 4.7 Hz, 1H), 7.56 (d, J = 8.8 Hz, 1H), 
7.42 (t, J = 8.0 Hz, 1H), 7.30–7.28 (complex, 2H), 7.24 (d, J = 
8.4 Hz, 2H), 7.20 (s, 1H), 7.13 (dd, J = 2.0 Hz, 8.4 Hz, 1H), 7.03 
(dd, J = 2.4 Hz, 8.4 Hz, 1H), 6.94 (d, J = 8.8 Hz, 2H), 4.69 (s, 
2H), 4.06 (t, J = 5.6 Hz, 2H), 3.66 (q, J = 6.4 Hz, 2H), 3.1 (s, 
3H), 2.09 (quin, J = 6.0 Hz, 2H), 1.49 (s, 18H); 
13
C NMR 
(CDCl3, 100 MHz): δ 168.8, 163.7, 159.2, 158.6, 156.3, 153.3, 
150.4, 150.0, 132.4 (q, J = 32.4 Hz), 132.2, 130.3, 129.1, 128.4, 
125.3 (q, J = 272.3 Hz), 120.7, 119.7, 119.2 (q, J = 4.0 Hz), 
118.9, 114.8, 114.4 (q, J = 3.7 Hz), 83.2, 79.4, 66.6, 56.2, 39.2, 
37.8, 28.7, 28.5, 28.3; 
19
F NMR (CDCl3, 376 MHz,): δ -63.0; 




The title compound was synthesized with the bis-Boc 
protected guanylated compound (80 mg, 0.11 mmol), EtOH (2 
mL) and acetyl chloride (0.70 mL, 8.8 mmol). The title 
compound was obtained as a sticky solid (60 mg, quant.). A 
small amount was purified by HPLC in order to obtain an 
analytically pure sample.  
Rf: 0.25 (10% MeOH: 90% DCM); IR (cm
-1
): 3339, 1627, 
1328, 1126, 935, 737; 
1
H NMR (CD3OD, 400 MHz): δ 7.53–7.50 
(complex, 2H), 7.44 (d, J = 2.4 Hz, 1H), 7.37 (d, J = 7.7 Hz, 1H), 
7.30-(d, J = 8.7 Hz, 2H), 7.20-7.18 (complex, 2H), 7.08 (dd, J = 
8.7, 2.4 Hz, 1H), 6.96 (d, J = 8.4 Hz, 2H), 4.74 (s, 2H), 4.08 (t, J 
= 6.0 Hz, 2H), 3.41 (t, J = 6.8 Hz, 2H), 3.15 (s, 3H), 2.07 (quin, J 
= 6.0 Hz, 2H); 
13
C NMR (CD3OD, 125 MHz): δ 170.2, 160.8, 
159.4, 159.0, 158.8, 154.8, 137.9, 133.9 (q, J = 32.4 Hz), 132.4, 
130.8, 126.9, 126.6, 126.3 (q, J = 270.0 Hz), 123.2, 121.6, 121.4 
(q, J = 3.7 Hz), 117.2, 116.4, 116.1 (q, J = 3.2 Hz), 115.1, 66.3, 
59.7, 40.2, 39.7, 29.7; 
19
F NMR (CD3OD, 376 MHz,): δ 76.9, -
64.3; HRMS (ESI): m/z calcd for C26H27F3N5O2S (M+H)
+
 
530.1832, found 530.1827. 
5.1.39.  N-(4-(3- (Dimethylamino)propoxy)benzyl) -6-
(3-(tr i f luoromethyl)phenoxy)benzo[d] thiazol -2-
amine  tr i f luoroacetate  (14e ) 
The title compound was synthesized according to general 
procedure F with 6e (30 mg, 0.063 mmol), paraformaldehyde (36 
mg, 0.64 mmol), NaBH4 (24 mg, 0.64 mmol), TFA (0.6 mL) and 
MeOH (3 mL). After purification by HPLC the title compound 
was obtained as a semi-solid (18 mg, 53%). 
Rf: 0.18 (10% MeOH: DCM); 
1
H NMR (CD3OD, 400 MHz): 
δ 7.57–7.53 (m, 2H), 7.49 (d, J = 2.4 Hz, 1H), 7.42 (d, J = 8.4 
Hz, 1H), 7.39 (d, J = 8.8 Hz, 2H), 7.24–7.22 (complex, 2H), 7.19 
(dd, J = 8.8, 2.4 Hz, 1H), 7.00 (d, J = 8.4 Hz, 2H), 4.64 (s, 2H), 
4.13 (t, J = 5.6 Hz, 2H), 3.357 (m, 2H), 2.94 (s, 6H), 2.23 (m, 
2H); 
13
C NMR (CD3OD, 100 MHz): δ 169.6, 160.0, 159.9, 153.8, 
142.3, 133.9 (q, J = 32.6 Hz), 132.2, 130.6, 130.0, 129.1, 126.7 
(q, J = 270.1 Hz), 122.7, 121.0 (q, J = 3.7 Hz), 120.7, 118.0, 
116.0, 115.8 (q, J = 3.5 Hz), 114.7, 66.1, 56.9, 43.8, 25.9; 
19
F 
NMR (CD3OD, 376 MHz): δ -77.0, -64.3; HRMS (APCI): m/z 
calcd for C26H26O2N3F3S (M)
+.
 501.1692 found 501.1697. 
  
5.1.40.  ter t -Buty l  (3-(4 -(( (6-(4 -
cyanophenoxy)benzo[d] thiazol -2-
y l)amino)methyl)phenoxy)propyl)carbamate  ( 10f)  
The title compound was synthesized according to general 
procedure A with the thiazole amine 1f (350 mg, 1.32 mmol) and 
the aldehyde 9
17
 (402 mg, 1.44 mmol). Compound 10f was 
obtained as a solid (304 mg, 54%) after purification by column 
chromatography [25% EtOAc: 75% hexanes]. 
Rf: 0.25 (25% EtOAc: 75% hexanes); M.P:143-144 °C; IR 
(cm
-1
): 3395, 3182, 2974, 2226, 1685, 1248, 1055, 980, 820, 
1
H 
NMR (CDCl3, 400 MHz): δ 7.58 (d, J = 8.8 Hz, 2H), 7.48 (d, J = 
6.4 Hz, 1H), 7.31-7.28 (complex, 3H), 7.01-6.96 (m, 3H), 6.87 
(d, J = 8.0 Hz, 2H), 4.77 (s, 1H), 4.55 (s, 2H), 4.01 (t, J = 6.0 Hz, 
2H), 3.33 (q, J = 6.0 Hz, 2H), 1.98 (quin, J = 6.4 Hz, 2H), 1.43 
(s, 9H), 
13
C NMR (CDCl3, 100 MHz): δ 167.7, 162.4, 162.3, 
158.8, 156.2, 155.5, 149.5, 134.3, 129.3, 119.5, 119.0, 117.6, 
115.0, 114.7, 113.4, 105.8, 66.0, 49.2, 38.1, 29.7, 28.6, HRMS 
(APCI): m/z calcd C29H30O4N4S (M)
+.
 530.1988, found 530.1984. 
5.1.41.  4-((2- ((4- (3-
Aminopropoxy)benzyl)amino)benzo[d] thiazol -6-
y l)oxy)benzonitr i le  tr if luoroacetate  (6f)  
To the Boc-protected compound 10f (70 mg, 0.13 mmol) in 
dry DCM (3 mL) was added sat. HCl in MeOH (1.5 mL). The 
reaction mixture was stirred under nitrogen atmosphere at 
ambient temperature for 24 h. The reaction mixture was diluted 
with MeOH (5 mL) and solvent was removed in vacuo to give a 
sticky solid 6f (50 mg, quant.). A small amount was purified by 
HPLC in order to obtain an analytically pure sample  
Rf: 0.18 (10% MeOH: 90% DCM); IR (cm
-1
): 2937, 2227, 
1670, 1124, 720; 
1
H NMR (CD3OD, 400 MHz): δ 7.70 (d, J = 8.8 
Hz, 2H), 7.52 (d, J = 8.8 Hz, 1H), 7.46 (d, J = 2.4 Hz, 1H), 7.37 
(d, J = 8.8 Hz, 2H), 7.12 (dd, J = 2.4 Hz, 8.4 Hz, 1H), 7.07 (d, J 
= 8.8 Hz, 2H), 6.98 (d, J = 8.8 Hz, 2H), 4.60 (s, 2H), 4.13 (t, J = 
5.6 Hz, 2H), 3.17 (t, J = 7.6 Hz, 2H), 2.16 (quin, J = 6.0 Hz, 2H), 
13
C NMR (CD3OD, 100 MHz): δ 169.6, 164.2, 159.5, 150.9, 
150.6, 135.6, 132.1, 130.2, 120.3, 119.9, 119.9, 118.7, 115.8, 
114.7, 106.5, 66.4, 38.8, 28.5; 
19
F NMR (CD3OD, 376 MHz): δ -




5.1.42.  2-(3-(4 -(( (6-(4 -
Cyanophenoxy)benzo[d] thiazol -2-
y l)amino)methyl)phenoxy)propyl)guanidine  
tr i f luoroacetate  (7f)  
The title compound was synthesized according to general 
procedure E with 6f (45 mg, 0.11 mmol), 1H-pyrazole-1-
carboxamidine hydrochloride (23 mg, 0.16 mmol), DIPEA (0.04 
mL, 0.2 mmol) and DMF (1 mL). Removal of the solvent in 
vacuo gave a sticky solid (45 mg, 90%) which was further 
purified by preparative HPLC. 
Rf: 0.20 (10% MeOH: 90% DCM); IR (cm
-1
): 3320, 2231, 
1661, 1458, 1085, 815; 
1
H NMR (CD3OD, 400 MHz): δ 7.71 (d, 
J = 9.2 Hz, 2H), 7.55 (d, J = 8.4 Hz, 1H), 7.52 (d, J = 2.4 Hz, 
1H), 7.38 (d, J = 8.8 Hz, 2H), 7.18 (dd, J = 2.4 Hz, 8.8 Hz, 1H), 
7.09 (d, J = 8.8 Hz, 2H), 6.99 (d, J = 8.8 Hz, 2H), 4.62 (s, 2H), 
4.09 (t, J = 6.0 Hz, 2H), 3.42 (t, J = 3.6 Hz, 2H), 2.09 (quin, J = 
6.0 Hz, 2H), 
13
C NMR (CD3OD, 150 MHz): δ 169.6, 164.0, 
159.8, 159.0, 158.8, 151.1, 148.8, 135.6, 131.3, 130.3, 120.5, 
119.9, 119.5, 119.1, 118.8, 115.8, 114.8, 106.5, 66.2, 39.7, 29.7; 
19
F NMR (CD3OD, 376 MHz): δ -77.0; HRMS (ESI): m/z calcd 
for C25H25N6O2S (M+H)
+
 473.1760, found 473.1739.  
5.1.43.  ter t -Buty l  (3-(4 -(( (6-(4 -
cyanophenoxy)benzo[d] thiazol -2-
y l)(methyl)amino)methyl)phenoxy)propyl)carbamate  
(11f)  
The title compound was synthesized according to general 
procedure B with 10f (260 mg, 0.490 mmol), dry THF (15 mL), 
NaH (47 mg, 1.2 mmol) and MeI (83 mg, 0.59 mmol). After 
column chromatography purification [25% EtOAc: 75% hexanes] 
compound 11f was obtained as a semi-solid (180 mg, 69%).  
Rf: 0.27 (25% EtOAc: 75% hexanes); IR (cm
-1
): 3355, 3061, 
2225, 1699, 1163, 835, 734; 
1
H NMR (CDCl3, 400 MHz): δ 7.61-
7.56 (complex, 3H), 7.31 (d, J = 2.4 Hz, 1H), 7.24 (d, J = 8.4 Hz, 
2H), 7.04 (dd, J = 2.4, 8.8 Hz, 1H), 6.99 (d, J = 8.8 Hz, 2H), 6.87 
(d, J = 8.8 Hz, 2H), 4.76 (s, 1H), 4.70 (s, 2H), 4.02 (t, J = 6.0 Hz, 
2H), 3.34 (q, J = 6.4 Hz, 2H), 3.14 (s, 3H), 1.98 (quin, J = 6.0 
Hz, 2H), 1.43 (s, 9H), 
13
C NMR (CDCl3, 100 MHz): δ 168.8, 
162.6, 159.1, 158.8, 156.1, 149.0, 134.3, 129.2, 128.1, 128.1, 
119.7, 119.5, 119.0, 117.5, 114.9, 113.2, 105.7, 79.4, 66.0, 56.4, 
38.2, 38.1, 29.7, 28.6, HRMS (APCI): m/z calcd for 
C30H32O4N4S (M)
+.
 544.2139, found 544.2142. 
5.1.44.  4-((2- ((4- (3-
Aminopropoxy)benzyl)(methyl)amino)benzo[d] thiaz
ol-6-y l)oxy)benzonitr i le  tr i f luoroacetate  (12f)  
The title compound was synthesized according to general 
procedure C with 11f (75 mg, 0.14 mmol), DCM (2 mL) and sat. 
HCl in dioxane (2 mL). The title compound was obtained as an 
oil (65 mg, quant.). A small amount was purified by HPLC in 
order to obtain an analytically pure sample.  
Rf: 0.20 (10% MeOH: 90% DCM); IR (cm
-1
): 3381, 2978, 
2226, 1706, 1250, 838;
 1
H NMR (CD3OD, 400 MHz): δ 7.70 (d, 
J = 9.2 Hz, 2H), 7.57 (d, J = 8.8 Hz, 1H), 7.52 (d, J = 2.4 Hz, 
1H), 7.32 (d, J = 8.8 Hz, 2H), 7.16 (dd, J = 2.4, 8.8 Hz, 1H), 7.08 
(d, J = 8.8 Hz, 2H), 6.98 (d, J = 8.4 Hz, 2H), 4.78 (s, 2H), 4,13 (t, 
J = 5.6 Hz, 2H), 3.21 (s, 3H), 3.17 (t, J = 7.2 Hz, 2H), 2.17 (quin, 
J = 5.6 Hz, 2H), 
13
C NMR (CD3OD, 100 MHz): δ 170.9, 164.0, 
160.0, 151.0, 149.7, 135.6, 132.2, 130.3, 129.8, 120.8, 119.9, 
119.8, 118.8, 116.1, 114.8, 106.8, 66.4, 57.3, 38.7, 38.7, 28.5; 
19
F 
NMR (CD3OD, 376 MHz): δ -77.0; HRMS (APCI): m/z calcd for 
C25H24O2N4S (M)
+.
 444.1616, found 444.1614. 
5.1.45.  2-(3-(4 -(( (6-(4 -
Cyanophenoxy)benzo[d] thiazol -2-
y l)(methyl)amino)methyl)phenoxy)propyl)guanidine  
tr i f luoroacetate  (13f)  
The title compound was synthesized according to general 
procedure E with 12f (55 mg, 0.11 mmol), 1H-pyrazole-1-
carboxamidine hydrochloride (25 mg, 0.17 mmol), DIPEA (0.04 
mL, 0.2 mmol) and DMF (1 mL). Removal of the solvent in 
vacuo gave a sticky solid (55 mg, 92%) which was further 
purified by preparative HPLC. 
Rf: 0.22 (10% MeOH: 90% DCM); IR (cm
-1
): 3345, 2984, 
2224, 1654, 1243, 1111, 926, 832; 
1
H NMR (CD3OD, 400 MHz): 
δ 7.70 (d, J = 8.8 Hz, 2H), 7.55 (d, J = 8.8 Hz, 1H), 7.49 (d, J = 
2.4 Hz, 1H), 7.30 (d, J = 8.4 Hz, 2H), 7.11 (dd, J = 2.4, 8.8 Hz, 
1H), 7.07 (d, J = 9.2 Hz, 2H), 6.97 (d, J = 8.8 Hz, 2H), 4.75 (s, 
2H), 4.08 (t, J = 6.0 Hz, 2H), 3.41 (t, J = 3.2 Hz, 2H), 3.16 (s, 
3H), 2.09 (quin, J = 6.0 Hz, 2H); 
13
C NMR (CD3OD, 100 MHz): 
δ 170.9, 164.1, 160.1, 150.9, 135.6, 132.5, 130.3, 129.8, 120.8, 
120.0, 119.8, 118.8, 118.8, 116.0, 114.8, 106.8, 66.2, 57.2, 39.8, 
38.6, 29.8; 
19
F NMR (CD3OD, 376 MHz): δ -77.0; HRMS 
(APCI): m/z calcd for C26H26N6O2S (M)
+.
 486.1838, found 
486.1842. 
5.1.46.  4-((2- ((4-
Hydroxybenzyl)amino)benzo[d] thiazol -6-
y l)oxy)benzonitr i le  (16f)  
The title compound was prepared according to the general 
procedure A except with 4-hydroxybenzaldehyde. The thiazole 
amine 8f (252 mg, 0.94 mmol), 4-hydroxybenzaldehyde (172 mg, 
mmol) and p-TSA (8 mg, 0.05 mmol) were dissolved in toluene 
  
(125 mL) and refluxed for 7 days. After removal toluene in 
vacuo, dry MeOH (50 mL) and NaBH4 (100 mg, 2.6 mmol) were 
added and the mixture refluxed overnight. The title compound 
was obtained as a solid (220 mg, 63%) after purification by 
column chromatography [50 % EtOAc: 50 % hexanes], purity 
90% by LC analysis. A small amount was purified by HPLC in 
order to obtain an analytically pure sample. 
Rf: 0.36 (50 % EtOAc: 50 % hexanes); M.P: 217–222 °C; IR 
(cm
-1
): 3327, 3019, 2849, 2479, 2291, 2234, 2113, 1739, 1725, 
1595, 1572, 1543, 1503, 1450, 1426, 1373, 1354, 1230, 1218, 
1185, 1165, 1104, 1090, 974, 923, 861, 812, 718, 678, 668; 
1
H 
NMR (400 MHz, DMSO-d6) δ 9.35 (s, 1H), 8.51 (d, J = 5.8 Hz, 
1H), 7.80 (d, J = 8.5 Hz, 2H), 7.57 (d, J = 2.5 Hz, 1H), 7.44 (d, J 
= 8.6 Hz, 1H), 7.19 (d, J = 8.1 Hz, 2H), 7.10 – 6.97 (m, 3H), 6.73 
(d, J = 8.1 Hz, 2H), 4.46 (d, J = 5.2 Hz, 2H). 
13
C NMR (151 
MHz, DMSO) δ 166.5, 162.13, 162.12, 156.6, 148.1, 134.6, 
131.5, 128.9, 128.6, 118.8, 118.7, 118.6, 117.3, 115.1, 113.7, 
104.5, 47.0; HRMS (APCI): m/z calcd. for C21H15N3O2S (M+H)
+
 
374.0963, found, 374.0958. 
5.1.47.  4-((2- ((4- (3-
(Dimethylamino)propoxy)benzyl)amino)benzo[d] thi
azol-6-y l)oxy)benzonitr i le  (14f)  
To a solution of 16f (40 mg, 0.11 mmol) in THF (15 mL) was 
added dimethylaminopropylchloride hydrochloride (384 mg, 2.4 
mmol) and K2CO3 (878 mg, 6.4 mmol). The reaction mixture was 
stirred at 50 ℃ for 4 days with the progress of the reaction 
monitored by LC, 70% conversion to the title compound. A 
portion was purified by HPLC in order to obtain an analytically 
pure sample. 
Rf: 0.15 (10% MeOH: 90% DCM); IR (cm
-1
):3392, 3328, 
2975, 2928, 1678, 1599, 1552, 1503, 1456, 1420, 1382, 1238, 
1203, 1184, 1140, 1088, 880, 837, 802, 723, 674; 
1
H NMR 
(CD3OD, 600 MHz) δ 7.75 – 7.70 (complex, 2H), 7.53 (d, J = 8.7 
Hz, 1H), 7.48 (d, J = 2.4 Hz, 1H), 7.42 – 7.37 (complex, 2H), 
7.12 (dd, J = 8.7, 2.5 Hz, 1H), 7.11 – 7.07 (complex, 2H), 7.02 – 
6.97 (complex, 2H), 4.63 (s, 2H), 4.14 (t, J = 5.7 Hz, 2H), 3.40 
(m, 2H), 2.97 (s, 6H), 2.25 (m, 2H); 
13
C NMR (CD3OD, 150 
MHz) δ 170.3, 164.65, 164.64, 160.38, 160.37, 152.18, 136.32, 
132.26, 131.0, 121.4, 120.5, 120.0, 119.6, 116.6, 115.7, 107.6, 
66.8, 57.7, 50.4, 44.5, 26.6. HRMS (APCI): m/z calcd for 
C26H27N4O2S (M+H)
+.
 459.1849, found 459.1846. 
5.1.48.  4-((2- ((4- (3-
(dimethylamino)propoxy)benzyl)(methyl)amino)benz
o[d] thiazol -6-y l)oxy)benzonitr i le  (15f)  
The title compound was synthesised according to the general 
procedure F with 6f (65 mg, 0.15 mmol), dry THF (10 mL), 
paraformaldehyde (146 mg, 4.8 mmol), NaBH4 (78 mg, 2.1 
mmol) and TFA (2.5 mL) the reaction mixture stirred for 48 
hours. The title compound was obtained as an oil (100 mg, 
quant.). A small amount was purified by HPLC in order to obtain 
an analytically pure sample. 
Rf: 0.31 (10% MeOH: 90% DCM); IR (cm
-1
): 2929, 2855, 
2227, 1681, 1598, 1548, 1502, 1457, 1366, 1251, 1233, 1177, 
1131, 1050, 926, 836, 800, 722; 
1
H NMR (CD3OD, 600 MHz) δ 
7.74 – 7.69 (complex, 2H), 7.56 (d, J = 8.7 Hz, 1H), 7.50 (d, J = 
2.5 Hz, 1H), 7.34 – 7.30 (complex, 2H), 7.11 (dd, J = 8.7, 2.5 Hz, 
1H), 7.10 – 7.06 (complex, 2H), 7.01 – 6.96 (complex, 2H), 4.78 
(s, 2H), 4.14 (t, J = 5.7 Hz, 2H), 3.38 (dd, J = 9.1, 6.6 Hz, 3H), 
3.18 (s, 3H), 2.97 (s, 6H), 2.24 (dq, J = 7.7, 5.7 Hz, 2H); 
13
C 
NMR (CD3OD, 150 MHz) δ 170.8, 164.0, 159.6, 150.8, 150.6, 
135.4, 132.7, 130.1, 120.5, 120.0, 119.7, 118.6, 115.9, 114.6, 
106.6, 66.0, 56.90, 56.87, 43.7, 38.4, 25.8. 
19
F NMR (376 MHz, 
MeOD) δ -76.8; HRMS (APCI): m/z calcd for C26H29N4O2S 
(M+H)
+.
 473.2011, found 473.2005. 
5.2. Biological evaluations 
5.2.1.  Calcium inf lux  assay  
Ca
2+
 responses were measured using FLIPR
TETRA
 and Calcium 
4 dye (Molecular Devices, CA, USA) using the neuroblastoma 
cell line SH-SY5Y for the N-type hCaV2.2 assay
40, 41
 and HEK 
293T expressing recombinant hCaV3.2 for the T-type assay. SH-
SY5Y and hCaV3.2 HEK 293T cells were plated at 40,000 and 
10,000 cells per well, respectively, in 384-well flat clear-bottom 
black plates (Corning, NY, USA) and cultured at 37°C in a 
humidified 5% CO2 incubator 48 h. The medium was removed 
and cells loaded with 20 μl/well Calcium 4 dye reconstituted in 
assay buffer containing (in mM) 140 NaCl, 11.5 glucose, 5.9 
KCl, 1.4 MgCl2, 1.2 NaH2PO4, 5 NaHCO3, 1.8 CaCl2 and 10 
HEPES pH 7.4 and incubated for 30 min at 37°C in a humidified 
5% CO2 incubator. For CaV2.2 assays, 10 μM nifedipine (CaV1 
blocker) was added to the dye. Ca
2+
 fluorescence responses were 
recorded using excitation 470–495 nm and emission 515–575 nm 
for 10 s to set the baseline, then again 600 s after addition of 
compounds at various concentrations and for a further 300 s after 
addition of 90 mM or 40 mM KCl for CaV2.2 and CaV3.2 
responses, respectively. 
5.2.2.  Data analys is  
Curve fitting was achieved using GraphPad Prism Version 6 
(GraphPad Software Inc, San Diego, CA, USA) with nonlinear 
regression with log[inhibitor] versus normalized response and 
variable Hill slope for dose-responses. Data were represented as 
mean ± 95% CI and SEM from triplicates in Tables 1-4, and 
mean ± SEM from n = 3 – 4 independent experiments in Figure 
4. 
 
5.2.3.  In vitro rat  plasma s tabil i ty  s tudies  
The in vitro stability assay was according to a reported 
procedure.
42
 To rat plasma (1 mL), at 37 °C was added the a 
MeOH stock of desired compound (final concentration 120 μM). 
At regular time points (0, 15, 30, 45, 60, 120, 240, 480, 1440 
min) an aliquot (50 μL) was removed and added to ice-cold 
acetonitrile containing, 120 μM quinoline as the internal 
standard, in order to deproteinize the plasma. The solution was 
centrifuged at 3000 rpm for 10 min at rt and the supernatant was 
diluted with equal volume of Milli-Q water and analysed by 
HPLC. The same procedure was repeated with 0.01 M PBS 
buffer instead of rat plasma for blank study. 
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